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resumo O cancro da mama triplo-negativo (TNBC) é uma heterogénea e 
complexa doença que actualmente ainda não dispõem de terapias 
direcionadas devido à falta de alvos terapêuticos presentes em outros 
tipos de cancro da mama, tais como a presença de receptores hormonais 
(receptores de progesterona (PR) e receptores de estrogénio (ER)) assim 
como de receptores de factores de crescimento humano 2 (HER2). 
Muitos dos pacientes de TNBC respondem muito bem aos tratamentos 
comuns dados aos pacientes que sofrem com cancros, mas infelizmente 
quando esses tratamento não são eficazes e TNBC volta, já se torna um 
tipo de cancro muito difícil de tratar. Neste projecto de investigação 
temos o objectivo de melhorar as terapias direcionadas para TNBC via 
duas abordagens conceptualmente diferentes. A primeira consiste na 
identificação de genes essenciais à sobrevivência de TNBC sob 
condições de hipóxia, onde hipotetizamos que a inactivação de tais genes 
seja “synthetic lethal” com terapias antiangiogénicas (AA). 
                                                    Na segunda parte, olhamos para a senescência das células cancerosas 
como uma vulnerabilidade que pode ser explorada usando um “one-two 
punch model” como abordagem terapêutica. Em primeiro lugar 
induzindo senescência via uma combinação de tratamento com 
Palbociclib com uma diminuição de cinase-dependente de ciclina 2 
(CDK2), seguido de um tratamento com ABT-263, um agente senolítico 
que promove apoptose prefencialmente em células senescentes sobre 
células não-senescenctes. 
                                                    Com este projecto pretendemos contribuir, não apenas para o 
melhoramento de terapias direcionadas para pacientes com TNBC, mas 
também para outros tipos de cancros, uma vez que estes conceitos podem 
ser extendidos a diferentes tipos de cancro. 
                                                     
  
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
keywords triple negative breast cancer, synthetic lethality, hypoxia, angiogenesis, 
antiangiogenic therapies, resistance and senescence 
 
 
 
abstract Triple-negative breast cancer (TNBC), a heterogeneous and complex 
disease entity, lacks targeted therapies due to the absence of common 
therapeutic targetable features that exist in other types of breast cancer 
(BC). TNBC patients generally respond very well to standard 
chemotherapy, but when TNBC recurs is often very hard to treat. In this 
project, we aimed at improving TNBC targeted therapy via two 
conceptually different approaches. The first one consisted of the 
identification of essential genes for the survival of TNBC cancer cells 
under hypoxia, where we hypothesized that inactivation of such genes 
would be then synthetic lethal with antiangiogenic therapies. Thus 
contributing to the improvement of this class of drugs to which patients 
often acquire resistance.  
In the second part of this project, we aimed at exploring senescence as a 
vulnerability in cancer cells that can be therapeutically targeted using a 
one-two punch model. In a first step senescence is induced via a 
combination of Palbociclib (CDK4/6 inhibitor) treatment with Cyclin-
dependent kinase 2 (CDK2) impairment; and in a second step, TNBC 
induced senescence cells were treated with ABT-263, a senolytic agent 
that promotes apoptosis preferentially on senescence cells over non-
senescence cells. 
With this project, we contributed not only to the so needed improvement 
of target therapies for TNBC patients but also to other tumors, once these 
different approaches can be extended to other cancer types. 
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1. Introduction  
1.1. Cancer  
 
1.1.1. Cancer overview 
 
Cancer is a collection of related diseases caused when cells in the body grow in an 
uncontrolled and abnormal fashion compromising normal cells’ function in the process.1–3 
Cancer cells, in contrast to normal cells, undergo a process of loss of specialization in which 
gain the ability of continuous proliferation. In a healthy organism, cells’ self- sacrifice —
apoptosis— is the rule that enables survival. This suicide mechanism allows metazoans to 
eliminate cells that put at risk whole body’s survival.4,5 From this perspective, cancer cells 
possess the capability to disrupt the most fundamental rules of cell behavior that underlie the 
basis for the building and maintaining the homeostasis of multicellular organisms.6  
Our understanding of the carcinogenesis process has increased significantly in the 
last two decades. It is now clear that cancer is the result of a multistep mutagenic process.7 
Such process often leads to mutations in genes that control important pathways of the cell 
cycle, cell proliferation, and survival, thus creating a deregulation on these pathways that are 
essential for tumor establishment.5,8 There are many types of genetic alterations accountable 
for the genetic basis of cancer that result in widespread deregulation of gene expression 
profiles, such as, subtle changes like deletions or insertions, as well as alterations in 
chromosome number, chromosome translocations and gene amplifications.6–10 Genetic 
instability has proved to be, in many cases, the motor of tumor progression and 
heterogeneity. Some mutations in certain genes are more prone to lead to cancer than others. 
Usually, they are grouped in two classes, the proto-oncogenes, and the tumor suppressor 
genes. While in the first cancer is driven by the gain of a function mutation, in the second 
the opposite happens, therefore there is a loss of function mutation.6,11 
Cancer represents the leading cause of deaths in developed countries and the second 
in developing countries. The forecasts that in the next years’ cancer diagnose will increase 
have to do mostly with population growth and aging.12,13 
There are many factors which can promote the necessary mutations to tumor 
emergence. For instance,  adoption of cancer-causing behaviors, such as smoking and sun 
exposure (X-rays and ultraviolet radiation), unhealthy diets, obesity and physical inactivity 
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are significant risk factors.14–16 Clearly, age plays a decisive role here, among the elderly 
population cancer incidence is increased. Several factors contribute to this observation, such 
as the decreased immune surveillance, accumulation of genetic mutations, a longer lifetime 
of exposure to carcinogens and age-related hormonal alterations. 
Epigenetics, along with genetic abnormalities also represents a very important 
process in the earliest stages of neoplasia. There are many data showing that almost in every 
type of human cancer there is a hypermethylation of the promoter regions of key regulatory 
genes, which is linked with inappropriate transcription leading to gene silencing.17,18 
Modern cancer biology proposes that tumor progression is the result of a multi-gene, 
multi-step clonal selection within the original clone, following a Darwinian adaptive system. 
This selection can occur from a single cell of origin19 and leads to a ‘refinement’ of cancer 
cells with more and more proliferation and survival advantage, therefore leading to more 
aggressive subpopulations.20–22 This is easily understandable against current knowledge that 
populations of tumor cell are more genetically unstable than of normal cells, so in the 
primary tumor there is a mix of subclonal populations constantly and sequentially being 
selected to an increasing genetically and biological abnormal state (Figure 1).19 
 
Figure 1: Clonal evolution from normal cells to primary tumors and metastases.23  
Each colored area represents a cell colony with a specific set of mutations accumulated in the progeny of a 
single most recent common ancestor (MRCA) cell. Time progresses to the right. The height of each colored 
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area represents the quantity of cells in the colony. New mutations are represented by stars and may originate 
from an established colony. The figure shows that these new mutations can originate in any part of the tumor 
and then competes for space and resources with the others. 
 
Evidence shows that metastatic dissemination is usually the last step in the primary 
tumor progression.24 It can take years until the genetic and epigenetic changes in the primary 
tumor to occur before it becomes mature enough to spread.25 Metastasis only occurs when 
the tumor has grown to a size that has likely allowed a clonal selection of cell mutations that 
give cancer cells that ability,25 and it is the cause of the majority of cancer deaths.26 
 
1.1.2. Hallmarks of cancer 
 
Weinberg et al24, believe that the complexity of cancer can be reduced to a small 
number of underlying principles. These principles are what we call the hallmarks of cancer. 
Currently, they consist of eight common traits to all cancers, complementary to each other, 
that together govern the transformation of normal to cancer cells. Namely, they are self-
sufficiency in growth signals, insensitivity to antigrowth signals, evading apoptosis, limitless 
replicative potential, sustained angiogenesis, tissue invasion and metastasis, reprogramming 
of energy metabolism and evading immune destruction. Alongside with these hallmarks, 
genome instability and tumor-promoting inflammation are described as two enabling 
characteristics for the acquirement of these hallmarks.27,28. In Figure 2 is depicted an 
overview of the hallmarks of cancer.  
A progressive and multistep acquisition of activating mutations in oncogenes or 
inactivating mutations in tumor suppressor genes are largely the drivers of tumor progression 
despite the variability of the genetic and epigenetic landscapes across different cancers.29 In 
fact, studies30,31 have shown that it is often the case that cancer diseases are “addicted” to 
the activation and maintenance of activity of oncogenes in order to keep the malignant 
phenotype.   
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Figure 2: The hallmarks of cancer and its therapeutic targets.28 
Drugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have 
been developed and are in clinical trials or in some cases approved for clinical use in treating certain forms of 
human cancer. Additionally, drugs are being developed to target each of the enabling characteristics and 
emerging hallmarks, which also hold promise as cancer therapeutics. The drugs listed are but illustrative 
examples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action in 
development for most of these hallmarks. 
 
 
1.1.3. Cancer treatment 
 
The most common cancer therapies can be divided into two categories, one being (1) 
treatments targeting general cancer mechanisms, which are not tumor/tissue-specific; and 
(2) treatments targeting tumor/tissue-specific mechanisms/phenotypes, which are referred as 
targeted therapies.32 
Currently, the majority of the treatments fall into the first category, which is 
comprised by surgery, chemotherapy, and radiotherapy, these are the oldest treatments and 
over the decades they have been highly effective in extending the survival of cancer patients 
and even eradicating some sorts of tumors.33 The second category includes targeted therapy 
and hormone therapy which have been greatly developed in recent years. Usually, most of 
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the oncology patients receive a  combination of these treatments, and the type of treatment 
given depends on the type and stage of the disease.34  
When possible, surgery is performed with the intent to remove the entire tumor, but 
sometimes that is not feasible, due to the damage that the complete removal would make in 
an organ, and only a part of the tumor is removed. When performed in early stages surgery 
remains to be the most effective treatment of primary tumors.35 
Radiotherapy was first used in the 20’s and since then it was improved significantly.36 
Not much later, in the 40’s, the principle that the systematical administration of drugs could 
induce tumor regression was established in when Goodman and Gilman tested the first 
chemotherapy treatment by injecting a ‘nitrogen mustard’ compound in patients with 
advanced non-Hodgkin’s lymphoma and observed that the mediastinal and lymphatic 
masses regressed.37 Oftentimes, these two treatments are used together as they complement 
each other. Despite the great advances made in these treatment techniques efficiency, there 
is still a major drawback that cannot be ignored, which is the fact that they are not tumor 
specific, implying that normal cells are also targeted and thus leading to undesirable side 
effects more or less severe.35 Both treatments consist of inducing DNA damage that in 
principle impairs cell division and triggers apoptosis. Furthermore, the treatment for a first 
cancer is associated with an increased risk of developing a second primary cancer when 
compared with the general population.38  
Targeted therapy refers to the more recent anti-cancer drugs (set apart of the common 
chemotherapeutical drugs) that can be separated into two types: small-molecule inhibitors 
and humanized monoclonal antibodies.  
With regard to the small-molecule inhibitors, these drugs are designed to interfere 
with specific molecular targets that play key roles in cancer progression (particular features 
common to cancer cells).39 They do so by taking advantage of the metabolic differences 
between normal and cancer cells, therefore such drugs can interfere with altered cell 
programs, mainly active in cancer cells, limiting the damage to the normal cells.40  
These therapies work in one of four ways: (1), blocking signals/pathways that cancer 
cells use to make new cancer cells, (2) delivering toxic substances that kill or damage cancer 
cells, (3) stimulating immune cells to destroy cancer cell and (4) blocking the growth of new 
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blood vessels around cancer cells, starving the cancer cells from nutrients essential for their 
growth. In sum, we can say that they are developed towards specific molecular targets 
directly involved in the development of the hallmarks of cancer.28 In Figure 2 is possible to 
see some examples of correlations between the drugs and the effects on the hallmarks of 
cancer. Thus, the challenges regarding targeted therapy consist in identifying valid targets 
as well as the subsequent drug development in such a way that the toxicity and off-target 
effects are very limited. Unfortunately, tumors that were initially sensitive to targeted 
therapies often end up developing drug resistance.41 Mutations during treatment and other 
adaptive responses, such as an increase in the expression of the therapeutic target or 
concomitant activation of alternative signaling pathways are one of the reasons for drug 
resistance.42,43 These phenomena have to do with the heterogeneity of the tumor, what 
happens is that upon targeted treatment the tumor is put under a pressure that leads to the 
selection, and later proliferation, of a minor drug-resistance cell subpopulation among the 
numerous tumor cells present in the original tumor.28,43 
With the increasing of genetic tools researchers start to use the concept of synthetic 
lethality in order to tackle this gain of drug resistance to small-molecule inhibitors targeted 
therapy.  Two genes are said to be synthetic lethal if a mutation of either alone is compatible 
with viability but mutation of both leads to death.44 From this concept, one can foresee that 
targeting a gene that is synthetic lethal to a cancer-relevant mutation should lead to a more 
efficient elimination of cancer cells while sparing normal ones.9,45 A great example proving 
this concept was discovered in breast cancer where researchers found toxicity of Poly (ADP-
ribose) polymerase (PARP) 1 and 2 inhibitors specifically in BRCA1 and BRCA2 mutant 
cells. This observation has already been clinically validated with success.46,47 
Immunotherapy is another promising, exciting and ground-breaking therapy field, 
for both advanced and metastatic cancers. For many decades’ researchers had hoped to 
modulate the body natural immune system to efficiently identify and attack cancer cells.48 
Establishing this type of anti-cancer defense is hard because the immune system by itself has 
evolved to recognize and eliminate foreign agents while leaving body’s own tissue 
untouched. The problem is evident, cancer cells are also native to the body, therefore, in 
many ways, indistinguishable from normal cells3 and often coexist in an equilibrium with 
the immune system.49 Furthermore, there are cases during the progression of the disease, in 
which cancer cells are capable of high jacking the immune system converting it into a 
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support structure for cancer development.50 Howbeit, regardless of the lack of understanding 
on the precise mechanism through which the immune system interacts with cancer, the 
immunotherapy objective is both to boost and to restore the immune system with the ability 
to detect and attack cancer cells.51,52 Recent studies have already allowed a shift on the 
standard of care for patients with advanced melanoma disease (metastatic), considered 
incurable until the date,  that now can be treated with potentially curative instead of palliative 
intent.53 With this promising results, it is expected that immunotherapy will still gain more 
and more relevance in the next years as new results from clinical trials are known, as well as 
the possibility of combining immunotherapy with other types of therapies.48,54 
Despite all the promising results, in general, target therapies suffer from one same 
important aspect that contributes to the lack of durable success of these types of therapy. 
That aspect is the lack of biomarkers that allow a proper stratification of patients to receive 
the most appropriated targeted therapy.55 Hopefully, the foreseen era of stratified and 
personalized therapy will enable tailored therapies to improve the outcomes and to reduce 
toxicity, but that future is still dependent on numerous challenges to be overcome. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
1.2. Breast Cancer 
 
1.2.1.   Breast cancer overview 
 
Breast cancer (BC) is the type of cancer more commonly diagnosed (30% of the new 
cases)  and the second leading cause of cancer death in women in the United States.56 Breast 
cancer is a collection of diseases with diverse origins, clinical characteristics, responses to 
therapy and outcomes. Over the years BC has been subdivided into different types and sub-
types in an attempt to better classify different patient’s prognosis and consequently to give 
them the better treatment option available that best suits the different BC types. BC can arise 
from different parts of the breast. The majority of them originates in the breast lobules, which 
are composed of glands that produce the milk, and in the milk ducts, the “pipes” that connect 
lobules to the nipple (Figure 3). These distinct origins cause that there is a multitude of 
different histological types of BC.  
Ductal carcinoma is the most common malignancy of BC, as well as the primary 
cause of death among women worldwide57 with an incidence of 50-80%.58 Ductal 
carcinomas can be divided into two types: the Ductal carcinoma in situ (DCIS) and the 
invasive ductal carcinoma (IDC). DCISs are considered to be a noninvasive form of BC. In 
this type of BC, cancer cells replace normal epithelial cells of the ducts, making them and 
the lobules expand, but without ever grow beyond the layer where they originated. IDCs, in 
its turn, are invasive forms of BC, which means that these BC cells manage to expand beyond 
the walls of the glands or ducts in which they originated.  
 The second most prevalent subtype of BC is the invasive lobular carcinoma (ILC) 
representing between 5-15 %.58 In the others BC subtypes are included categories such as 
medullary, neuroendocrine, tubular, apocrine, metaplastic, mucinous, inflammatory, 
adenoid cystic and micropapillary types.59  
Breast cancer can be staged using the TNM (tumor node metastasis) classification 
system accordingly to the stage of disease they are in; the T refers to the primary tumor size, 
the N to the near lymph nodes that are involved and M to the metastasis stage (presence or 
absence).60 With the TNM method patients receive a classification from 0 (in situ tumor, 
cancer is still at a very early stage) to IV (invasive cancer already spread to distant parts of 
the body).  
9 
 
 
 
Figure 3: Normal breast with invasive ductal carcinoma (IDC) in an enlarged cross-section of the duct.57 
Scheme of the women’s breast anatomy and the location of the IDC. 
 
High-throughput technologies, such as gene expression microarray studies, have led 
to a new taxonomy of breast cancer based on their molecular characteristics. The more 
traditional molecular distinctions take into consideration the status (presence or absence) of 
hormone receptors —estrogen receptor (ER) and progesterone receptor (PR)— and, the 
amplification of the growth-promoting protein, human epidermal growth factor receptor 2 
(HER2).61–63 Studies based on the gene expression revealed five subtypes of breast cancer: 
luminal A (HR+ and/or PR+/HER2-) and B (HR+ and/or PR+/HER2+/-), basal-like/ triple-
negative (HR- and PR-/HER2-), HER2-enriched (HR- and PR-/HER2+) and normal-like 
(similar to luminal A).64 Basal-like BC definition was not yet internationally accepted, 
whereas some groups base their definition recurring to immunohistochemistry (IHC) studies, 
some others opt by microarray profiling.64 
In the last two decades’ mortality rates had suffered reductions, due mainly to the 
development of early detection, prevention and novel treatments. Nevertheless, the statistics 
show that incident rates have been increasing, which is believed to be closely related to the 
increasing and improvement of diagnostic techniques.65 
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1.2.2. Triple-negative breast cancer (TNBC) 
 
TNBC owns its name to the fact that this subtype of BC is negative to all the three 
common markers in breast cancer already described (ER, PR and HER2).64,66,67 Meaning 
that the proliferation and survival of this type of BC are neither dependent on hormones 
(estrogen and progesterone) neither on the amplification of HER2 receptors. A direct 
implication of this phenotype is its resistance to conventional hormonal therapy, such as 
tamoxifen or aromatase inhibitors, as well as to therapies targeting HER2 receptors, the case 
of trastuzumab.68–70 Due to the lack of recognizable molecular targets, chemotherapy, 
radiotherapy and surgery are still the best treatment, both in early or advanced stages of 
TNBC.66,71,72 In the cases which TNBC becomes resistant to these treatments the tumors 
often become more aggressive and unresponsive making of TNBC a type of cancer 
associated with a poor outcome,66 only 30% of metastatic TNBC cancer patients survive 5 
years.72 TNBC tumors account for 10-17% of all BC carcinomas64,67 and represent about 
15% of all invasive breast cancers.67 Unlike others low-grade BC carcinomas, risks of TNBC 
are higher with increasing parity and waist-to-hip circumference ratio, suggesting that 
genetic and social factors come together in an intimate way, observed by the fact that TNBC 
has a higher prevalence among young black and Hispanic women.67  
 An early and correct diagnosis of TNBC is of paramount importance, once it has 
implications in the choice of systemic therapy to give to the patients, so for instance, by 
avoiding false diagnosis, patients with positive expression of one of those receptors could 
have benefits from endocrine therapies or HER2 targeted drugs. The diagnose is done by 
IHC, where the levels of protein expression of PR, ER and HER2 are assessed. Thus, now 
the challenge is to be able to subtype TNBC to better identify molecular-based therapies. 
Due to the great heterogeneous disease that characterizes TNBC this type of BC displays a 
complex genomic landscape that results in a wide spectrum of transcriptional, histological 
and clinical differences.72 From such differences, inevitably, there is the emergence of 
tumors with different grades of aggressiveness; and although TNBCs are, in its majority, 
considered as high-grade tumors, there is also a subset of well-characterized low-grade 
TNBCs that displays a favorable outcome.73 So it is of pivotal importance to improve the 
subtyping of TNBCs.74–76 
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1.3. Hypoxia and angiogenesis 
 
Capillary blood vessels are composed of endothelial cells and pericytes.77,78 In 
embryogenesis blood vessels arise via two different processes, namely, vasculogenesis, in 
which endothelial cells arise from progenitor cell types, and angiogenesis, the process by 
which new capillaries sprout from existing vessels.78,79 In physiological conditions, the 
vasculature is at a quiescent state in adult mammals with the exception of female 
reproductive cycles processes, such as ovulation, menstruation, implantation and pregnancy, 
in which new blood vessels form through angiogenesis.78 It is a complex and highly 
regulated process, but when unregulated it is the cause of diseases such as arthritis and 
diabetes.79  
Like normal cells, in order to survive, tumor cells also need to have access to oxygen 
and nutrients as well as an ability to evacuate metabolic wastes and carbon dioxide.28 Today 
there is no doubt about the importance of angiogenesis in the role of solid tumor 
development. Evidence shows that a tumor that grows to a small size of few millimeters in 
diameter requires the induction of new capillary blood vessels80 and, on the other hand, in 
the absence of an adequate vasculature tumor cells undergo necrosis and/or apoptosis 
resulting in tumor impairment.78 Thus, in order to overcome this growth inhibition, tumor 
cells induce the formation of new blood vessels from pre-existing ones.81 This process is 
known as tumor angiogenesis and is not only essential for primary tumor growth but also for 
the metastatic spread,  since the presence of a new vasculature in the tumors fosters the 
entrance of tumor cells into circulation, increasing metastasis occurrence chances and thus 
is associated with poor prognostic outcomes.80–82 During this process, there is an ‘angiogenic 
switch’. This switch consists in a transition from a small-sized avascular tumor mass to a 
state where blood vessels develop promoted by the release of diffusible activators of 
angiogenesis by the tumor.78,83 This process is initiated when cancer cells experience 
hypoxia conditions, which is characterized by a cellular or tissue level of oxygenation lower 
than normal that triggers a physiological stimulus to which the organism tries to respond 
accordingly to the demands of the respiring tissues.82,84,85 Hypoxic regions are present in 
many tumors types as a result of rapid proliferation and deviating angiogenesis. The O2 
levels in tumors are very heterogeneous with some regions having a partial pressure of 
oxygen (pO2) of less than 5 mmHg, compared to a pO2 of 30-50 mmHg in the same, non-
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cancerous, organs.86 In the case of BC, reported to be one most hypoxic types of cancer, 
nearly 60% of the tumors have a pO2 lower than 2.5 mmHg, whereas in healthy tissue values 
lower than 12.5 mmHg were not found.87 
The response to hypoxia conditions is mainly mediated by the hypoxia-inducible 
factors (HIFs).82,88 HIFs are a family of transcription factors that control important 
pathophysiological pathways and, in particular, emerged as the master regulators of oxygen 
tension homeostasis.89 There are around 1000 genes that have their regulation dependent on 
HIF, most of them involved in the adaptations to hypoxia. These include genes regulating 
metabolism, blood-vessel growth, cell division and inflammation. HIF-1 is a heterodimeric 
protein comprising a constitutively expressed β subunit and a α subunit tightly regulated by 
oxygen availability.84,90 
Under hypoxic condition, HIF is activated and upregulates the expression of a set of 
genes with pro-angiogenic functions. One of those genes is the vascular endothelial growth 
factor (VEGF) family (VEGF-A, VEGF-B, VEGF-C, VEGF-D and PIGF (placental growth 
factor)) which are signal proteins secreted by both tumor and endothelial cells (ECs) in 
response to hypoxia.91 VEGFs bind to the vascular endothelial growth factor receptor 
(VEGFR) family, signal mainly through VEGF receptor 2 (VEGFR-2)92 but also through 
VEGFR-1 and VEGFR-3, three transmembrane cell surface tyrosine kinases, which activate 
the intracellular pathway leading to permeability, proliferation, migration and survival of 
ECs (Figure 4). 
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Figure 4: An overview of the activation of the angiogenic pathway.93 
VEGFR is activated upon binding of VEGF, which results in activation of several downstream pathways, 
leading to angiogenesis. Neuropilin 1 (NRP1) can, when activated by VEGF-A, potentiate VEGFR-2’s 
function. TIE2 activation through binding of Angiopoietin-1/2 (Ang-1/2) promotes angiogenesis. PDGFR 
activation upon PDGF binding has a vessel stabilizing effect by increasing pericyte coverage. Activation of the 
Fibroblast Growth Factor Receptor (FGFR) by the Fibroblast Growth Factor (FGF) promotes angiogenesis and 
EC proliferation. Furthermore, the pro-angiogenic signaling molecules αvβ3 and αvβ5 integrins are activated 
through several components of the extracellular matrix. Notch activation by the Delta4 ligand on the tumor cell 
membrane has a pro-angiogenic effect as well. 
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1.4. Senescence  
 
The word senescence derives from the Latin senex, which means old man or old age. 
At a cellular level senescence refers to a phenomenon that involves deteriorative processes 
culminating in the irreversible cell proliferation arrest, to what we call cellular senescence.94 
It is a cellular response, to endogenous or exogenous stresses, that allows cells to maintain 
alive under the condition of cellular cycle arrest characterized by changes on a 
morphological and physiological level.  
Hayflick and colleagues were the first to describe the cellular senescence 
phenomenon by showing that primary fibroblasts (normal human cells) had a limited ability 
to replicate when kept in culture for long periods of time.95 This work revealed that after 
many cell doublings, the replicative potential of those cells was exhausted resulting in the 
presence of viable cells with no capability to proliferate even though they had an abundance 
of growth factors, nutrients and space.95 Today it is known that this particular type of cellular 
senescence is triggered by the telomere shortening and it is called replicative senescence.96 
The dysfunctional telomeres trigger senescence via the p53 tumor suppressor protein (p53) 
pathway (Figure 5).94  
One other strong, and telomere independent, senescence inducer mechanism is the 
DNA double strands breaks (DSBs) lesions.97 Oxidative stress and other DNA damaging 
agents can cause DNA base damage and single-strand breaks which, on its turn, can be 
converted to DBSs during the replication and repair processes. In the context of cancer 
treatment, the formation of DNA DSBs can arise from ionization radiation, topoisomerases 
inhibitors and other cytotoxic chemotherapeutic drugs,98,99 which are notably effective 
senescence inducers, capable of both inducing it in tumor cells or in the surrounding normal 
cells.100 The precise mechanism behind this type of induction is unknown, but such lesions 
provoke a constant DNA damage response signaling, which is characterized by the long-
term presence of nuclear DNA damage foci that contains activated DNA damage repair 
proteins including p53. 
Mitogenic signals can also be strong inducers of senescence.101 The best examples of 
this type of induction are the senescence responses that are provoked by certain oncogenes. 
This phenomenon has come to be known as oncogene-induced senescence. In some cases, 
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the overexpression of oncogenes induces molecular and morphological changes that cause 
the cells to stop dividing, instead of promoting an increase in proliferation. Earlier studies 
on this type of senescence response were done in mutant HRAS (HRASV12) cells, which 
chronically stimulates the mitogen-activated protein kinase (MAPK) signaling pathway, 
shown that it promotes senescence in normal cells.102 Since then other components of the 
MAPK pathway have been linked to the induction of senescence when overexpressed or 
present in oncogenic forms.103,104 Furthermore, cells can also undergo senescence in 
response to many other mitogenic stimuli such as the overexpression of growth factor 
receptors such as the HER2,105 chronic stimulation by cytokines106 and other forms of intense 
mitogenic stimulation.107 Independently of the initiating event, mitogenic signals end up 
engaging either or both of the two major tumor suppressor pathways: p53/p21 and the cyclin-
dependent kinase inhibitor 2A/Retinoblastoma-associated protein (p16INK4a/p-RB) pathways 
(Figure 5),  known to establish and maintain cellular senescence.108 In fact, the chronic 
activation or overexpression of p53, p-RB, p21 or p16INK4a is commonly sufficient to induce 
senescence.102,109 These are two complex pathways with numerous regulators and effectors 
that, in addition, can cross-regulate each other.110,111 Both p53 and p-RB are master 
transcriptional regulators, thus these pathways control the senescence response mainly 
through widespread changes in gene expression. p21 is a downstream effector and p16INK4a 
is a positive upstream regulator of p-RB, and both are cyclin-dependent kinase inhibitors 
that work as strong negative regulators of the cell cycle. p53, in particular, has a major role 
as a tumor suppressor112 and it is regarded as one of the most important regulators of cell 
fate.113 It acts by restricting proliferation through numerous cell cycle checkpoints leading 
the cell to apoptosis or cellular senescence.  
As we still struggle to fully understand how senescence works, there is evidence 
demonstrating that senescence has both beneficial and detrimental roles. On one hand, 
transient cellular senescence induction followed by tissue remodeling favors the removal of 
damaged cells and acts as a tumor-suppressor mechanism against oncogenic development. 
On the other hand, if this process is persistent and it is not followed by the ability to eliminate 
such cells it will directly influence the renewable of the tissues and becomes a detrimental 
process.114 Broadly, it is possible to say that the role of senescence is to allow the organism 
to remove unwanted cells. 
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Figure 5: Senescence controlled by the p53 and p16–pRB pathways.94  
Senescence-inducing signals usually engage either the p53 or the p16/p-RB tumor suppressor pathways. Some 
signals, such as oncogenic RAS, engage both pathways. p53 is negatively regulated by the E3 ubiquitin-protein 
ligase HDM2 (MDM2 in mice), which facilitates its degradation, and HDM2 is negatively regulated by the 
alternate-reading-frame protein (ARF). Active p53 establishes the senescence growth arrest in part by inducing 
the expression of p21, a cyclin-dependent kinase (CDK) inhibitor that, among other activities, suppresses the 
phosphorylation and, hence, the inactivation of pRB. Senescence signals that engage the p16–pRB pathway 
generally do so by inducing the expression of p16, another CDK inhibitor that prevents pRB phosphorylation 
and inactivation. pRB halts cell proliferation by suppressing the activity of E2F, a transcription factor that 
stimulates the expression of genes that are required for cell-cycle progression. E2F can also curtail proliferation 
by inducing ARF expression, which engages the p53 pathway. So, there is reciprocal regulation between the 
p53 and p16–pRB pathways. 
 
Together with apoptosis —also a cellular response to endogenous or exogenous 
stimuli but which results in a programmed cell death— these two mechanisms are the most 
efficient to remove those damaged cells.114 Both are conceptually identical to each other, it 
is possible to say that senescence is an apoptosis resistance mechanism, and p53 protein is 
the major regulator of both processes. Although it is not still very clear what makes a cell to 
whether undergo a senescence or apoptotic pathway, the cell type seems to be a relevant 
factor, for instance, damaged epithelial cells and fibroblasts are more prone to senescence 
than damaged lymphocytes, which tend to undergo apoptosis.94  
Over the years the characterization of the cellular senescence state has been 
improving. As is expected there is not a single characteristic to be exclusive of the 
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senescence state. Instead to distinguish senescent cells from other non-dividing cell 
processes, such as quiescent or other types of terminally differentiated cells, a set of several 
features comprising both morphological changes and molecular markers are used.  
The absence of proliferation markers is obviously one of those markers. For instance, 
the absence of the proliferative marker 5-bromodeoxyuridine is an essential condition to 
certificate the state of senescence.94 This synthetic nucleoside, analogue to thymidine, is 
incorporated by the cell during the DNA synthesis in the S phase of the cell cycle, thus by 
detecting the incorporated chemical it is possible to measure the rate of proliferation.94  
At a morphological level cellular senescence is clearly visible by the changes in the 
phenotype, cells become larger, often with doubling in volume, flat and in some cases with 
a multinucleated appearance.115 These basic characteristics on their own are a good 
indication for a potentially cellular senescence state, however, they are still insufficient. 
Together with these microscope visible features, the histochemical staining for 
senescence-associated β-galactosidase (SAβ-gal) activity was one of the first and most 
consensual biomarkers to be used to identify cellular senescence.101,116 This activity is based 
on the overexpressed lysosomal content of senescent cells. It reflects the enlargement of the 
lysosomal compartment as a consequence of the increased lysosomal biogenesis in senescent 
cells.117  This activity is linked with an increase in autophagy, which is an effector 
mechanism of senescence.116 For the most of the mammalian cells SA-β-gal activity 
detection is made at pH 4.0 but for senescence, it is only sensed around pH 6.0.117 The 
simplicity of this assay and its apparent specificity for senescent cells have made of this 
biomarker one of the most extensively used. 
Another marker that can be used, is the senescence-associated heterochromatin foci 
(SAHF) which is a characteristic present in some, but not all, senescent cells.118 SAHF 
represents cytologically detectable heterochromatin domains that endorse altered expression 
of proteins that affect the chromatin structure. This heterochromatin main objective is to 
repress and contribute to the silencing of proliferation-promoting genes in the senescent 
cell.119 SAHF appears to be dependent on p16INK4a/p-RB pathway activation and have been 
strongly correlated with the irreversibility of senescence arrest.119 Although SAHFs are not 
present in all senescent cells, it has been proposed that, in cells that do not develop these 
structures, the p16INK4a/p-RB pathway might establish chromatin states that are functionally 
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equivalent to SAHFs due to the ability of pRB to complex in histone modifying enzymes 
that form repressive chromatin.94 Senescent cells can be identified by the cytological markers 
of SAHFs that are detected through favorable binding of DNA dyes, such as 4′,6-diamidino-
2-phenylindole.  
Alongside with these changes in chromatin organization and gene expression 
alterations, it is still necessary to mention yet another important biomarker to the 
identification of senescence, that is, the senescence-associated secretory phenotype (SASP). 
Many senescent cells overexpress genes that encode secreted proteins that can alter the tissue 
microenvironment. These include numerous proinflammatory cytokines, chemokines, 
growth factors and proteases.120,121 The complexity of the SASP proteins reflects the myriad 
of biological activities that it provokes. Some components of SASP can promote cell 
proliferation120,122 as well as stimulate new blood vessel formation.123 SASP secretions of 
the pro-inflammatory cytokines (interleukin-6 and 8), chemokines and macrophage 
inflammatory proteins directly or indirectly promote inflammation.120,124 Some other 
components, particularly transforming growth factor-beta, are known to trigger senescence 
in neighboring cells in a paracrine manner.114 One interesting feature of SASP is that it is 
primarily a property of cells that senesce owing to genomic damage or epigenomic 
perturbation, thus a cell that enters senescence via ectopic overexpression of p21 or p16INK4a 
do not express SASP as senescence feature.125 
Currently, it is hypothesized that SASP might have evolved together with the 
senescence response as a mechanism to both suppress the development of cancer and 
promote tissue repair in young organism126 through the promotion of an inflammatory 
microenvironment that stimulates the clearance of damaged and senescence cells by the 
immune system.114 However, the “dark side” (already mentioned above dual role of the 
senescence response) of the SASP secretome is only revealed later in life; when the age-
dependent accumulation of senescent cell creates sites of chronic inflammation and 
remodeling/healing features, which are permissive for the development, or at least the 
progression, of cancer through SASP factors known to fuel the deleterious effects of 
senescent cells.126 Also with age comes the decline of the adaptive immune system making 
it less likely that senescent cells will be cleared efficiently.127 So, senescent cells increase 
with age and can promote cancer initiation through their prominent feature of SASP 
secretions that, on their turn, can stimulate the infiltration of leukocytes which produce 
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reactive toxic moieties that can cause DNA damage.128,129 It seems that at some point, 
senescent growth arrest starts to lose its evolutive function of preventing cancer development 
and tissue damage, and instead it contributes to the exact opposite. 
An important question then is if the senescent state can be used as a therapeutic target. 
Recent studies have been emerging with promising results in this field.130 Nevertheless, 
cellular senescence remains very ambiguous and still raises a battery of questions remaining 
to be answered. 
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1.5. Objectives 
 
TNBC is a type of BC that is a remarkably heterogeneous and complex disease entity 
that lacks targeted therapies. And though a lot of women respond very well to the 
surgery/chemotherapy/radiotherapy treatment, when TNBC recurs or spreads it is, 
unfortunately, more difficult to treat than some other forms of BC. We very much need to 
find new treatments, both for patients with metastatic or advance TNBC, and for patients 
with an early stage to do a better job in preventing recurrences. 
The objective of this work is the improvement of breast cancer therapy by using two 
conceptually different approaches: (1) investigating the synthetic lethality with hypoxia; (2) 
exploiting senescence as a vulnerability in cancer cells that can be therapeutically targeted.  
(1) Tumor hypoxia is a common feature in cancer diseases and it can have dual roles. 
On one hand it can function as a drug resistance and as a driving oncogenic force, and on 
the other hand, it can prevent the growth of tumor cells. The development of antiangiogenic 
(AA) treatments, at first very promising, revealed to be a clinical failure conferring no 
enduring benefits to oncology patients. Thus, there is the need to improve the efficacy of AA 
therapies. This part of the project aims at doing so and consisted on the validation of a 
functional genetic CRISPR screen aiming to find synthetic lethal interactions with hypoxia. 
(2) A genetic screen aiming to find synthetic lethal partners with Palbociclib 
treatment in TNBC cell lines revealed not a synthetic lethality interaction but instead the 
induction of senescence with the cyclin-dependent kinase 2 protein (CDK2). This second 
part of the project aimed to further expand the validation of this finding to a larger TNBC 
cell line panel using different approaches (genetic and pharmacological) and subsequently 
test the efficiency of a senolytic drug (ABT-263) in specifically killing senescent cancer 
cells. 
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2. Results and discussion  
 
2.1. Finding synthetic lethal interactions with hypoxia in TNBC 
 
Most cancers grow in hypoxic conditions due to the lack of a proper functional 
vasculature able to support the physiological needs of the fast-growing malignant cells. It is 
in these hypoxic tumor areas that we find some of the most malignant cells.131 There are 
currently several targeted therapies to target and inhibit angiogenesis. Yet these anti-
angiogenic therapies have failed to show enduring anti-cancer responses and thus 
contributed marginally to improve overall survival of breast cancer patients in clinical trials. 
Here we aim at contributing to the improvement of anti-angiogenic treatments. To this 
purpose, we use hypoxia culturing conditions (1% O2) to mimic the effect of reduced tumor 
vasculature induced by this treatment in vitro. We choose a TNBC cell model because this 
type of BC lacks targeted therapies, has a bad prognosis and is, usually, more hypoxic than 
the other BC subtypes.132 In this study, we used a CRISPR/Cas9 technology approach to 
perform a genetic screen aiming at finding synthetic lethal interactions with hypoxia/anti-
angiogenic agents. The screen was performed with an epigenetic library since there is little 
knowledge about the regulation of the epigenome in hypoxia. 
The human TNBC line SUM159PT was infected with that library which contained 
5230 single guide RNA (sgRNA) sequences targeting chromatin modifiers and epigenetic 
regulators. The screen was maintained at a complexity of 1000-fold coverage (each sgRNA 
was present in approximately 1000 cells), and with a multiplicity of infection (MOI) of 
approximately 0.3 to avoid multiple integrations and thus confounding results due to 
passenger effect. Cells were seeded in three technical replicates for each arm, normoxia 
(21% O2), and hypoxia (1% O2), and collected also in triplicates in the time-point zero as a 
reference sample (Figure 6A).  
After culturing for 20 days, genomic DNA was isolated and the viral DNA was 
recovered by polymerase chain reaction (PCR), and analyzed by deep sequencing to identify 
the number of sgRNA inserts in the cell population. The results were analyzed using the 
MAGeCK software.133 Overall sgRNAs targeting essential genes were depleted in 
comparison to those targeting nonessential genes in both normoxia and hypoxia arms (Figure 
6B), indicating that technically the screen performed as intended. The M/A plot in Figure 
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6C represents the depletion of sgRNA at 1% O2 versus the mean reads per sgRNA at 21% 
O2. The ten candidate genes identified as top hits are indicated in Table 1. 
 
 
 
Figure 6: Synthetic lethality dropout screen layout and its hits. 
(A.) An epigenomic CRISPR library was used to infect SUM159PT TNBC cell line at a complexity of 1000 
and MOI of 0.3. Cells were collected at time-point zero (control) and cultured in 1% and 21% O2 for 20 days. 
The screen was designed with three biological replicates per arm and collected in three technical replicates. 
Lentiviral DNA was captured, PCR-barcoded for each technical replicate and sequenced using Illumina Hi-
Seq. (B.) In vitro screen controls, M/A plots of hypoxia vs. T0 and normoxia vs T0 in which the depletion 
(relative abundance 1% O2 / T0 and 21% O2 T / T0) of the control genes is plotted versus mean read per sgRNA 
(log 10 scale), non-targeting controls (NTC) are shown in blue and essential genes in orange. The plots show 
the depletion of essential genes while the non-targeting controls remain in the cloud in both oxygen tensions. 
(C.) M/A plot in which the depletion (relative abundance 1% / 21% O2) is plotted versus mean read per sgRNA 
(log 10 scale). The four top hits are shown in different colors (each one with at least 3 different sgRNAs to the 
same gene), the cut-off criteria for a gene to be considered a hit was a false discovery rate of < 0.003. 
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Table 1: Top 10 candidate genes hit list after screen analysis. 
neg | rank Gene ID Nr. of sgRNAs Neg | fdr 
1 RUNX1 18 0.00165 
2 HIF1AN 10 0.00165 
3 ASXL2 10 0.00165 
4 RBBP7 17 0.003713 
5 KAT2A 10 0.008911 
6 EP300 10 0.009076 
7 KDM3B 10 0.170438 
8 ZMYND11 15 0.316213 
9 TDRD7 10 0.833333 
10 SP140 18 0.857921 
 
When I arrived in the Bernards lab, the screen had been already performed and 
analyzed. I started my internship by validating the top four candidate genes: RUNX1, 
HIF1AN, ASXL2 and RBPP7. 
The first step was to assess the effect of hypoxia on the proliferation of the 
SUM159PT cell line on a long-term clonogenic assay. In Figure 7A is not possible to 
appreciate a strong difference in the colony formation assay, but quantification with cell titer 
blue (CBT) showed a statistically significant difference (Figure 7B) with a p-value of 
0,02707 at end stage. This indicated a slight sensitivity of this cell line to hypoxia that we 
aimed to increase further by interfering with the genes identified in the screen. 
 
Figure 7: Hypoxia condition (1% O2) does not significantly impair SUM159PT cell proliferation. 
SUM159PT cells were seeded at low density in a 6-well plate setting and cultured either at 21% or 1% O2 
conditions. (A.) Colony formation assays where cells were fixed and stained in each of the indicated time 
points. (B.) Growth curves from cell counts of the indicated time points (results from two biological replicates 
counted in duplicate). (Time points where p-values show statistical significance are indicated with (*); T=3, (p 
= 2,352E-06), T=9 (p =0,00239) and at T= 11 (p = 0,02707)). 
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2.1.1.  RUNX1 validation 
 
Runt-related transcription factor 1 (RUNX1) also known as acute myeloid leukemia 
1 protein or Core Binding Factor subunit alpha-2 (CFBA2) is a protein that is encoded by 
the RUNX1 gene, which showed up as the strongest hit in the screen. CFBA2 can bind to 
the DNA as a monomer, but its affinity is enhanced 10-fold if it heterodimerizes with the 
Core binding factor subunit beta (CBFB), forming the Core binding factor (CFB) which is a 
transcription factor and it can bind to the core element of several different enhancers and 
promoters. RUNX1 binds DNA and is thought to be involved in the development of normal 
hematopoiesis.134 
For the validation of RUNX1, we individually cloned the six sgRNAs targeting 
RUNX1 that best scored on the screen into the pLentiCRISPR2.1 vector. These were used 
to produce lentivirus particles that transduced SUM159PT cells. In Figure 8A it is shown 
RUNX1 protein levels from SUM159PT cells infected with the six different sgRNAs.   
From all the six sgRNAs, only the cells infected with the sgRNA-RUNX1-11 showed 
a significant reduction in the levels of RUNX1 protein at the time-point zero (lysates 
harvested after puromycin selection). This result seemed to be correlated with the fact that 
this sgRNA was the one that had the strongest score in the screen (Table 6 in materials and 
methods section). However, over a period of 15 days, sgRNA-RUNX1-11 levels did not 
remain diminished and were in fact enriched over time (red boxes in Figure 8A).  
This transient loss of RUNX1 protein knockdown levels over time can be explained 
by the polyclonal population setting in which the experiment was performed. It is known 
that over time, certain knockouts confer cells with a proliferative disadvantage. What might 
be happening is that cells that have less RUNX1 knockdown levels take over the population 
by displaying proliferation advantage over the most efficiently RUNX1 knockdown cells. 
Furthermore, there is also the possibility that there are cells edited with a silent mutation that 
does not have impact on the protein synthesis or functions.135 
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Figure 8: RUNX1 validation.  
(A.) SUM159PT cells were transduced with sgRNA-RUNX1 (six different sgRNAs targeting RUNX1 and one 
non-targeting control gRNA) and seeded at time-point zero (T=0) after puromycin selection. Protein lysates 
were prepared at the same time and blotted for assessment of RUNX1 levels. Single gRNA-RUNX1-11 
displayed the strongest RUNX1 protein level reduction and these cells were followed up for further validation 
(red box) by being cultured in hypoxia or normoxia. At T=8 and T=15 cells were harvested and blotted for 
RUNX1.  RUNX1 protein levels get enriched over time. HSP90 was used as loading control. (B.) Transfected 
SUM159PT cells were isolated into single cell clones by Fluorescent Activated Cell Sorting after puromycin 
selection. Cells were harvested and blotted for RUNX1 protein levels. (C.) SUM159PT cells were transduced 
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with shRNA-RUNX1 (four different short hairpins targeting RUNX1 —shE5, shE6, shE7, shE9— and empty 
vector pLKO as control). Cells were harvested for protein and RNA analyses after puromycin selection. (D.) 
Parental cells were seeded at low-density in 6-well plate setting and allowed to attach overnight both at 21% 
and 1% O2 conditions. Cells were then treated with increasing doses of THZ1 (refreshed every 2 days) for a 
period of 7 days. Cells were fixed, stained and scanned. (E.) Parental cells were seeded at low-density (400 
cells per well in 96-well plate setting) and allowed to attach overnight both at 21% and 1% O2 conditions. Cells 
were then treated with increasing doses of THZ1 (refresh every 2 days) for a period of 5 days after which they 
were fixed, stained and scanned (three technical replicates per condition). (Unt. = untreated, NTC = non-
targeting control). 
 
For these reasons, a logical way to proceed is to validate the hits in monoclonal 
populations. In order to do so, we isolated single cell clones by Fluorescent Activated Cell 
Sorting (FACS) from these polyclonal populations. This experiment was performed right 
after the puromycin selection, in order to start with an enriched population of cells knockout 
for the targeted gene. Despite the technical difficulties in isolating such populations, we were 
able to grow some clones but, unfortunately, the results of the western blots never revealed 
a true RUNX1 knockout level (Figure 8B.). 
The fact that we could not achieve any RUNX1 knockout clones when trying to 
isolate monoclonal populations, nor observe any knockdown levels in the polyclonal setting, 
led us to think that RUNX1 might be an essential gene and thus its depletion display a 
straight lethal phenotype. In fact, RUNX1 knockout mice are embryonic lethal due to defects 
in liver hematopoiesis and central nervous system haemorrhages.136,137 In cancer this could 
still be a context-dependent event in SUM159PT cells. If this holds true, the absence of 
RUNX1 knockout in the western blots could be explained as the result of the outgrowth cells 
that were edited on a silent mutation (mutation in one nucleotide that does not display 
phenotype).135 
In an attempt to rule out or confirm this hypothesis, we next used a short hairpin RNA 
(shRNA) approach. This method leads to a knockdown of the target gene instead of a 
knockout. SUM159PT cells were transduced with lentivirus particles carrying five different 
shRNAs targeting RUNX1. Also with this approach, we did not detect reduced levels of 
RUNX1 RNA nor protein (Figure 8C). In fact, we even observed an upregulation of RUNX1 
transcripts in the shRUNX1 treated cells; this event makes sense if it is the case that this 
gene controls its own expression through a negative feedback loop and once the protein level 
decreases, the gene compensates by increasing its transcription resulting also in the 
upregulation of protein levels. Of relevance to mention that cells transfected with one of the 
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shRNAs (shRNA-E8) did not survive to the viral transduction and subsequent puromycin 
selection, which can also support the notion that RUNX1 is indeed a straight lethal gene in 
this particular cell line. 
RUNX1 has been known for its role in the development of several types of 
leukemia,136 and more recently it has also been found mutated in breast cancer.138,139 One 
study shows a putative correlation between the expression of RUNX1 and poor patient 
prognosis in TNBC patients with primary operable BC, where authors show that when 
RUNX1 protein levels are highly expressed the survival rate decreases compared to the 
low/absent RUNX1 expression.140 For this reason, in parallel to the genetic validation of the 
screen, we also pursued a pharmacologic validation of RUNX1 in the context of hypoxia. 
However, the direct targeting of transcription factors is not something easy to achieve,141 
especially as a cancer therapy due to the many roles that transcription factors have in non-
malignant cells. One way to pharmacologically inhibit general transcriptional machinery is 
through an indirect inhibition, for instance, the targeting of transcription co-factors.  
A recent study shows that THZ1, a selective covalent inhibitor of cyclin-dependent 
kinase 7 (CDK7), negatively impact the transcription activity of RUNX1 in Jurkat T-ALL 
cell.142 The same authors also used THZ1 in a TNBC work, where they show that TNBC, 
but not hormone receptor-positive breast cancer cells, are dependent on CDK7 
transcription.143 For these reasons we decided to use THZ1 to interfere with RUNX1 activity. 
Furthermore, THZ1 was never explored under hypoxia, and so it would still be novel to test 
it in this context. 
In Figures 8D and 8E are shown the results of THZ1 treatment in colony formation 
(CF) assays performed in 6 and 96-well plates settings. The CFs on the 6-well setting (Figure 
8D) did not show differences when cells were grown in hypoxia versus normoxia conditions 
upon increasing concentrations of THZ1 treatment. Even so, this experiment was also 
performed in a 96-well setting (Figure 8E) and here we observed a slight difference in the 
phenotype, cells cultured at 1% O2 showed a stronger cell proliferation impairment compared 
to when cultured at 21% O2. In order to clarify these discrepancies, the experiments must be 
repeated with better controls, for instance, take along cells to grow in hypoxia but without 
THZ1 treatment, because this slight difference in cell proliferation can be the result of 
hypoxia on itself (Figure 7B). Another point to be addressed is RUNX1 protein levels and 
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its target genes upon THZ1 treatment, to verify THZ1 effect on RUNX1 in this cell line in 
the tested oxygen tensions. 
Overall the experiments presented in this thesis suggest that RUNX1 does not 
validate as a screen hit and thus is not synthetic lethal with hypoxia. Using a CRISPR/Cas9 
approach, we only managed to obtain knockdown of RUNX1 with one gRNA (sgRNA-
RUNX1-11), but that phenotype was rapidly lost in the polyclonal population, preventing a 
proper conclusion about the theoretical synthetic lethality of RUNX1 with hypoxia. 
Monoclonal populations of CRISPR-RUNX1 edited cells also failed to produce RUNX1 
deficient cells. Additionally, the shRNA approach and qRT-PCR analyses further suggest 
that, indeed, RUNX1 might be a straight lethal gene in SUM159PT. With regard to the 
pharmacological approach, the results also did not show a synergy which encouraged us to 
pursue further experiments. 
In resume, due to the above presented technical limitations, we were never able to 
create RUNX1KO cells and thus, the synergy between RUNX1KO and hypoxia was never 
truly tested.  
 
2.1.2. HIF1AN validation  
 
HIF1AN gene encodes the hypoxia-inducible protein 1-alpha inhibitor (FIH1), an 
important protein in the cellular hypoxia adaptation that influences the expression of a large 
spectrum of genes dependent on the oxygen pressure variations.144,145 
The significant biological role of HIF1AN associated with the fact that it was the 
second strongest hit in the CRISPR screen giving synthetic lethality with hypoxia made it 
an interesting candidate gene for follow up validation. 
The same approach was taken to validate HIF1AN hit. Lentivirus particles carrying 
three sgRNAs targeting HIF1AN gene were produced and used to transduce SUM159PT 
cells. Efficient knockdown of FIH1 was confirmed by Western blot at different time points 
in a polyclonal cell population (Figure 9A). However, in a long-term colony formation assay, 
we did not observe any phenotype difference when cells were cultured at different oxygen 
tensions (Figure 9B). 
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Figure 9: HIF1AN validation. 
(A.) SUM159PT cells were transduced with sgRNA-HIF1AN (with three different gRNAs targeting HIF1AN 
gene and one non-targeting gRNA control) and seeded at time-point zero (T=0) after puromycin selection (left 
of panel A). Cells were also seeded at the end of CFs experiments, at time-point 11 days after puromycin 
selection (T=11) in both hypoxia and normoxia conditions (right on panel A). Protein lysates were harvested 
and prepared at the same time and blotted for assessment of FIH1 protein levels (red arrow). (B.) Transduced 
cells were seeded at low-density in a 6-well plate setting, and cultured for a period of 10 days (medium refresh 
every 3 days) at 21% and 1% O2 after which they were fixed, stained and scanned. 
 
Our conclusions are that, either even a residual level of FIH1 still present in the 
polyclonal population is enough to maintain its function, or either that the loss of HIF1AN 
is not synthetic lethal with hypoxia. We could also have isolate monoclonal population of 
complete HIF1AN knockout cells and repeat these experiments, but given the complete 
absence of phenotype with a polyclonal setting we did not think it was promising enough to 
move forward with the validation of this gene. 
 
2.1.3. ASXL2 and RBBP7 validation 
 
The same strategy was used in the validation of ASXL2 and RBBP7.  
Putative Polycomb group protein ASXL2 encoded by ASXL2 gene shown decent 
reduced protein levels at time-point zero and thus, those cells were cultured in hypoxia for a 
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period of 8 days (Figure 10A). ASXL2 impairment did not show any phenotype in 
combination with hypoxia conditions (Figure 10B). 
Histone-binding protein RBBP7 encoded by RBBP7 did not show protein reduction, 
at time-point zero, strong enough to justify a further evaluation on the synthetic lethality 
with hypoxia (Figure 10A). 
 
Figure 10: ASXL2 and RBBP7 validation 
(A.) SUM159PT cells were transduced with sgRNA-ASXL2 and with sgRNA-RBBP7 (both with three 
different sgRNAs targeting both genes and one non-targeting sgRNA control) and seeded at time-point zero 
(T=0) after puromycin selection. Protein lysates were harvested and prepared at the same time and blotted for 
assessment of ASXL2 and RBBP7 protein levels. (B.) Transduced cells were seeded at low-density in a 6-well 
plate setting, and were cultured for a period of 8 days (medium refresh every 3 days) at 1% O2 conditions after 
which they were fixed, stained and scanned. 
 
ASXL2 gene did not validate in a polyclonal setting despite some degree of protein 
reduction, and as similarly to HIF1AN, the total absence of phenotype in this setting made 
us not continue any further validation with monoclonal populations. 
Regarding the RBBP7 gene, we cannot properly conclude about its validation. The 
levels of protein were not reduced and, once this was the gene with the weakest score on the 
hits list, we did not further invest in its validation.  
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2.1.4. Discussion and conclusions 
 
From the four hits considered for validation, two of them did not validate, namely 
ASXL2 and HIF1AN. CFs assays where the level of protein was knocked down did not show 
any phenotype when cultured in hypoxic conditions. 
The other two hits, RUNX1 and RBBP7, also did not validate. Although in these two 
cases we cannot really rule out the possibility of a validation because we never managed to 
achieve truly knockouts cell populations, despite the several attempts and different methods 
to create such populations. 
Because RUNX1 was the strongest hit and thus the one that held a more promising 
phenotype, it was the hit in which we dedicated more effort. A pharmacological validation 
using a CDK7 inhibitor (THZ1) with the ability to interfere with the transcription of RUNX1 
was performed but failed in showing convincing results. Furthermore, recent studies report 
that RUNX1 inhibitors shown efficacy in impairing Triple-negative BCs,141 and it would be 
interesting to explore these findings in a context of hypoxia. Even more, recently was the 
discovery that the target genes of RUNX1 strongly overlapped with those of ASXL2,146 so 
the fact that both genes appeared in the top score hits might be related to this common target 
genes role under hypoxia. 
Several attempts in previous genetic screens with the aim to find synthetic lethality 
interactions with hypoxia have been performed. Screens using shRNA, CRISPR, several cell 
models, three targeted libraries (kinome, epigenome, hypoxia library) and yet all failed, 
demonstrating how hard it is to identify such interactions. The validation of this screen also 
falls within the scope of those results. We did not find any hit that has validated. 
Nevertheless, this does not mean that we should stop trying. For example, these screens 
could be performed in cells been treated with anti-angiogenic drugs (e.g. bevacizumab), 
because the response to genetic setting (in this case by culturing the cells in 1% O2) is always 
different when compared to a pharmacological setting, where you have off-target effect 
events promoted by the drugs that do not occur in the same way with the genetic editing. 
Another suggestion would be to perform these screens to find essential genes upon AA 
treatment in an in vivo setting.  A recent paper alerts for caution when interpreting in vitro 
results. The authors report that when comparing the results of in vitro and in vivo screens 
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experiments with the aim to identify essential genes for the survival of a type of brain cancer 
have shown almost no overlap,147 suggesting that the translation from in vitro to in vivo 
settings can be more complex than what we thought. 
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2.2. Cellular senescence as a vulnerability used to kill cancer cells. 
 
Aiming at finding synthetic lethal interactions with the CDK4/6 inhibitor Palbociclib, 
a former Ph.D. in our lab performed a genetic screen in 3 TNBC cell lines (HCC1806, CAL-
51 and CAL-120) using a shRNA kinome library. The results from the screen revealed 
cyclin-dependent kinase 2 (CDK2) as the strongest hit with multiple hairpins in the three 
cell line models. 
Palbociclib is a selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) 
already used in the clinic for treatment of ER-positive and HER-negative advanced breast 
cancer.148 TNBC are resistant to Palbociclib.149 We confirmed this by treating a panel of 
TNBC cell lines with Palbociclib in a long-term CF assay (Figure 11). Table 3 (Materials 
and Methods section) lists the most important driving mutations in each of the TNBC cell 
lines used in this study. 
 
Figure 11: Palbociclib treatment in a panel of TNBC cell lines. 
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Cell lines were seeded at low-density numbers and allowed to attach overnight before being treated with 
Palbociclib at increasing concentrations (medium and drug refreshed every 3 days). After 10 days of culture, 
cells were fixed and stained. (Unt. = untreated control).  
In general, we can conclude that all the tested cell lines are, to some extent, resistant 
to Palbociclib treatment. HCC1806 cell line showed more sensitivity, and CAL-51, along 
with SUM159PT, displayed milder sensitivity with higher drug concentrations. 
Literature and results from our lab showed that drug resistance (acquired or intrinsic) 
often develops by the reactivation of the inhibited pathway.150–152 So is not so surprising that 
we found a hit that is in the same pathway as CDK4/6 (the targets of Palbociclib). 
Furthermore, the targeting of the cell cycle, through CDKs inhibition, has the advantage of 
being a process in which cancer cells are more dependent than when compared with most of 
the cells in the human body, which are mainly in a quiescent state. 
However, when trying to validate this finding, CDK2KD in combination with 
Palbociclib treatment did not prove to be truly synthetic lethal. Instead, a significant number 
of cells survived upon treatment. Microscopic examination showed a different morphology 
of the remaining cells: increased size, flattened cytoplasm, and polynucleation. These cells 
appear not to be dividing, thus suggesting that they could be in a senescent or quiescent state. 
Further characterization using senescence-associated β-galactosidase (SA-β-gal) staining 
and biochemical markers of cellular senescence, for example, loss of phosphorylated RB and 
up-regulation of cyclin-dependent kinase inhibitor 2A (p16Ink4A), showed that these cells 
were indeed in a senescence state. Altogether, this screen revealed a strategy to induce 
senescence through the combination of Palbociclib treatment and CDK2 knockdown.  
Before I arrived in the lab, all the in vitro validation with shRNA had already been 
performed. The next step then would be to validate this model in vivo, because the ultimate 
goal of all translational cancer research is to bring the lab knowledge closer to the clinic. To 
this aim, we tested the model with CRISPR, since classical shRNA is often not a stable 
system to perform long-term in vivo experiments. 
This strategy to induce senescence could then be explored and used in a one-two 
punch model approach. In a first step, we would induce senescence in cancer cells and in a 
second step, eliminate them with a senolytic agent. 
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2.2.1. CRISPR /Cas9 (re)validation of the senescence inducible model in 
TNBC 
 
In order to generate stable CDK2KO clones to model the senescence phenotype in 
vivo (treatment with Palbociclib of CDK2KO tumors), we did a revalidation of the screen 
using a CRISPR/Cas9 approach in three TNBC cell lines. CAL-51 because it was one of the 
cell lines in which the shRNA screen was performed. SUM159PT because it is a cell line 
that was previously tested in mouse xenografts. Moreover, SUM159PT cells are cultured in 
5% FBS (half of what usually is used for culturing other cell lines), making it a suitable cell 
line for tumor engraftment once CDK2 is genetically inactivated. Finally, SK-BR-7 in order 
to have a better representation of TNBC heterogeneity and thus giving us a more robust 
model in case of validation.  
  
Figure 12: Palbociclib treatment in combination with CRISPR editing of CDK2 induces senescence in 
TNBC. 
(A.) Colony formation assays of three TNBC cell lines (SUM159PT, SK-BR-7 and CAL-51) seeded after 
complete puromycin selection. Cells were treated with Palbociclib in increasing concentrations for 7 days (drug 
refreshed every 2-3 days). (B.) CDK2 protein levels in all the cell lines 10 days after puromycin selection in 
polyclonal populations. (HSP90 as a loading control) (C.) Biochemical profile of CDK2 knockdown cells 
treated with Palbociclib (2 µM). SUM159PT cells were harvested 19 days after puromycin selection and with 
eight days of Palbociclib treatment; CAL-51, SK-BR-7 cells were harvested 26 days after puromycin selection 
and with 14 days of Palbociclib treatment. (Unt.= untreated control, NTC = non-targeting control). 
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CDK2KO and NTC cells were treated with Palbociclib (SUM159PT for eight days; 
CAL-51, SK-BR-7 for 14 days) and blotted for senescence markers (Figure 12C). 
SUM159PT showed the most pronounced reduction in proliferation upon Palbociclib 
treatment in combination with CDK2KO. In the other two cell lines, the differences in 
proliferation were not as pronounced as in SUM159PT. However, the cellular features of 
senescence previously described were observed after microscopic inspection. This 
observation is consistent with the fact that SUM159PT was the TNBC line with the most 
reduced CDK2 levels.  
When using CRISPR editing the goal is to get a complete knockout of the targeted 
protein, but as discussed in the previous section, often cells that are genetically edited have 
a proliferative disadvantage and overtime are less represented in the bulk population. This is 
one of the problems in doing these experiments in polyclonal cell population setting, as it 
was this case. It is notable an enrichment overtime for CDK2 protein level in SK-BR-7 and 
CAL-51 (Figure 12B-C). 
This correlation between the efficiency of CDK2KO levels and a visible phenotype in 
the CFs upon Palbociclib was also observed in SW1463, a colon cancer cell line, and to a 
less extent in two lung cancer cell lines (H1944 and H2122) where the phenotype is only 
observed at higher Palbociclib concentrations (Figure 13). 
  
 
Figure 13: Palbociclib treatment in combination with CRISPR editing of CDK2 induces senescence in 
other cancer types (lung and colon). 
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(A.) Colony formation assays of one CRC cell line (SW1463) and two lung cancer cell lines (H2122 and 
H1944) seeded after complete puromycin selection. Cells were treated with Palbociclib in increasing 
concentrations for 7 days (drug refreshed every 2-3 days). (B.) CDK2 protein levels in all the cell lines 10 days 
after puromycin selection in polyclonal populations. (HSP90 as a loading control). (C.) Biochemical profile of 
SW1463 CDK2 knockdown cells treated with Palbociclib (2 µM). Cells were harvested 26 days after 
puromycin selection and with 14 days of Palbociclib treatment. (Unt.= untreated control, NTC = non-targeting 
control). 
 
Common to the majority of these cell lines is the up-regulation of cyclin-dependent 
kinase inhibitor 1A (p21) (except in SK-BR-7) and the highly-decreased RB phosphorylation 
that occurs only in the combination of CDK2KO with Palbociclib treatment. With these 
expected senescence biomarkers and the observed reduction in proliferation on the CFs 
assays, we can say that Palbociclib treatment upon CDK2KO impairs cell proliferation via 
induction of a senescence state. These findings are not only applicable to TNBC but extended 
to other cancer types as well, as shown here with (one) colorectal and (two) lung cancer cell 
lines. 
Put together, these results suggest that the degree of CDK2 reduction might be 
correlated with the effectiveness of the induction and maintenance of a senescence 
phenotype. 
In the meantime, we had started in vivo pilot experiments to test the engraftment of 
CRISPR/Cas9 CDK2KO edited cells. Surprisingly, mice injected with CAL-51 and A549 
(lung cancer) CDK2KO cells showed a strong tumor growth impairment when compared to 
the growth of control tumors (CDK2 wild-type) (data not shown). These were not the 
circumstances in which we wanted to test our model. To fully recapitulate our in vitro 
phenotype, both arms —CDK2KO and CDK2 wild type-tumors— should have comparable 
tumor volume before Palbociclib administration. 
The observation that CDK2KO alone already provokes a strong tumor growth 
impairment made us consider other approaches for the in vivo experiment: to test an 
inducible shRNA-CDK2 system and the use of a small molecule inhibitor of CDK2. 
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2.2.2. Using doxycycline-inducible shRNA-CDK2 and Palbociclib treatment 
to induce senescence in TNBC 
 
The use of an inducible shRNA system that we could activate at any given moment 
was an option with which we could tackle the problem of using cells edited with 
CRISPR/Cas9 prior engraftment into the mice, as described in the previous section.  
Eight TNBC cell lines were transfected with doxycycline-inducible shRNAs 
targeting CDK2 (three different shRNA-CDK2, sh40/76/77, were used to minimize off-
target effects and to give more confidence to the study). As mentioned previously, CAL-51, 
CAL-120 and HCC1806 were used because the screen was performed on these cell lines and 
so the induction of senescence should, in theory, also validate using a shRNA inducible 
system. 
Firstly, we started by assessing the levels of CDK2KD in that panel of eight TNBC 
lines (Figure 14A) and performed CFs assays to evaluate cell proliferation when this 
CDK2KD inducible system was used in combination with Palbociclib versus CDK2KD alone 
(Figure 14B). 
CDK2KD levels upon doxycycline treatment were not equally reduced across the cell 
panel (Figure 14A). This was also verified observing under the microscope the level of 
expression of a red fluorescent protein (RFP) that functions as a reporter for shRNA 
induction in the used constructs. In other words, doxycycline activates both the shRNA 
system and the expression of RFP, which can be used to visually confirm the level of 
shRNA-CDK2 induction. We observed that not all cells were RPF-positive upon 
doxycycline, and in some cell lines, such as SK-BR-7 and CAL-120, we observed RFP signal 
in only 50% of the cells. This issue could be overcome with cell sorting, to isolate 
monoclonal populations. However, due to time limitations, these experiments were not 
performed and thus will not be discussed in this thesis. 
 
39 
 
   
 
Figure 14: CDK2 knockdown levels and its proliferation effect in a panel of TNBC cell lines. 
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A panel of TNBC lines was transfected with a doxycycline-inducible shRNA-CDK2 system (three different 
small hairpins with different sequences were used: shCDK2-40, shCDK2-76, shCDK2-77). (A.) Cells were 
seeded and protein lysates prepared at the same time for western blot assessment of CDK2 levels. The shCDK2 
inducible system does not have the same level of efficiency across the panel of cell lines. In the ‘Over Exp.’ 
image is shown the CDK2 levels with a longer exposure time to confirm that these are knockdowns and not 
knockouts. (B.) Cells were seeded at low densities in 6-well plate setting and treated with increasing 
concentration of Palbociclib up to 2 µM (refreshed every 3 days) for a period of 13-15 days, after which all the 
plates were fixed, stained and scanned. The control wells from SUM159PT are missing because cells detached 
due to overgrowth. (PD = Palbociclib; Unt. = untreated; dox = doxycycline).  
 
In only half of the cell lines (HCC1806, MDA-MB-157, HCC1937, HCC70) this 
system conferred a substantial CDK2 reduction on the protein level. In general, we can say 
that all the cell lines exhibited, within a broad range, sensitivity to Palbociclib treatment 
upon CDK2KD. CAL-120 was an exception since it did not show any visible impairment of 
proliferation, but it was one of the cell lines where CDK2 protein levels were the least 
reduced. In truth, to some extent, in the cases where CDK2KD was more efficient is visible a 
stronger proliferation reduction. For some cell lines (HCC1937, SK-BR-7 and HCC70), 
CDK2KD alone seemed to have a significant impairment in proliferation regardless of 
Palbociclib treatment.  
Another interesting observation was that, in virtually all cell lines, with a microscope 
observation it was possible to see cells with two totally distinct morphologies growing in 
clusters within the same wells. However, we could not find a strong link between these 
different morphologies with the RPF signal status. We would expect that cells with non-
senescence morphology would not show RPF signal, and the other way around for cells with 
a morphology of senescence, but it was not the case. The RPF signal was “randomly” 
distributed across these two morphological distinct phenotypes. 
Based on these experiments we concluded that CDK2KD confers more sensitivity to 
Palbociclib treatment, leading cells to a growth impairment that might be the result of 
entering into a senescence state. Moreover, there is a category of TNBC lines that are 
sensitive to CDK2KD. The results also suggest that the absence of phenotype in proliferation 
might have to do with the insufficient CDK2KD similarly to what we previously observed 
using the CRISPR approach. 
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From the eight cell lines used in the last panel, we selected five of them for further 
senescence characterization: the original cell lines where the screen was performed, CAL-
51, CAL-120 and HCC1806, alongside with SUM159PT and MDA-MB-157. In Figure 15 
are depicted the results of the experiments where we assessed for senescence biochemical 
biomarkers and looked at SA-β-galactosidase activity.  
 
Figure 15: Senescence induction in a panel of TNBC. 
A panel of five TNCB cell lines transduced with shRNA-CDK2 (sh76 and sh77) were treated with 
doxycycline (to induce CDK2 knockdown) in combination with Palbociclib or with Palbociclib alone as WT 
control, for a period of 10 days (Palbociclib was refreshed every 3 days and used at different concentrations 
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indicated below each cell line in (B.); new doxycycline was added daily to the medium to keep a constant 
expression of the shRNA inducible system). (A.) Cells were seeded for Western blot assessment of 
senescence biomarkers (p21, p16, p-RB), and for the levels of CDK2 and two of its binding partners (cyclin 
E and cyclin A). (B.) Cells were seeded for CF assay at low densities in 6-well plate setting and treated with 
Palbociclib (refresh every 3 days) for 6 days after which the shCDK2-76 ABT-263 untreated wells of all the 
plates were fixed and stained for the senescence biomarker SA-β-galactosidase.  
 
The Western blots show CDK2 levels generally reduced after doxycycline treatment 
and variable across the panel (Figure 15A). The phosphorylation levels of RB (p-RB) were 
downregulated in Palbociclib and Palbociclib + CDK2KD conditions, but to a greater extent 
in the former. Unfortunately, the blots for p16 and p21 did not technically work (proteins 
could not be detected, and thus are not included). Together, CDKs and Cyclins carefully 
regulate the cell cycle. CDK2 can bind to multiple cyclins (cyclin types A, B, D and E). We 
blotted for Cyclin E and A because those two are the preferred pairing cyclins of CDK2. 
Cyclin E is most active during G1 to S phase transition, while Cyclin A has its peak of 
activity during S and G2 phase. The results show that upon CDK2KD there is an impairment 
on the expression of both Cyclins, with Cyclin A being more affected than Cyclin E. Indeed, 
Cyclin A is equally downregulated with Palbociclib alone and Palbociclib in combination 
with doxycycline in CAL-51 and MDA-MB-157. Previous studies showed that Palbociclib 
alone can impair the levels of expression of Cyclin A and induce a quiescent state in primary 
liver cancer models.149  
As expected, in general, the untreated cells — no Palbociclib nor doxycycline—  did 
not stain for SA-β-galactosidase activity (Figure 15B) (in CAL-51 we observed background 
staining due to high cellular confluency). As for the cells treated with Palbociclib alone, 
there is some staining (mostly CAL-51 and MDA-MB-157) and the levels of p-RB are 
equally diminished in both conditions indicating that Palbociclib alone already induced some 
degree of senescence in these cell lines. HCC1806 and MDA-MB-157 were the cell lines 
with the most pronounced CDK2KD, which correlates with a more pronounced SA-β-gal 
activity staining. 
To further strengthen the senescence characterization of these cells, we could also 
have looked to the senescence-associated secretory phenotype (SASP)153 which can be 
detected by mRNA analysis. Nevertheless, with the presented senescence biomarkers we 
have shown that CDK2KD in combination with Palbociclib treatment induces senescence in 
these cell lines.  
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2.2.3. Killing senescence cells with ABT-263 - genetic validation 
 
Naturally, the only good cancer cell is a dead one. At this point the plan was to apply 
the second punch by treating senescent cells with ABT-263, a senolytic compound that has 
already demonstrated efficiency in eliminating senescent cells.154,155 
Using the same panel of TNBC cell lines we tested the effect this drug at two different 
concentrations. 
 
 
Figure 16: ABT-263 treatment of shCDK2 + Palbociclib senescence cells. 
A panel of five shRNA-CDK2 (sh76 and sh77) transduced TNBC cell lines were treated for a period of 10 
days with doxycycline (to induce CDK2 knockdown) in combination with Palbociclib or with Palbociclib alone 
as WT control (Palbociclib was refreshed every 3 days and used at different concentrations indicated in Figure 
15; new doxycycline was added daily to the medium to keep a constant expression of the shRNA inducible 
system), before being seeded for CFs at low densities in 6-well plate setting and treated with Palbociclib and 
ABT-263 (refresh every 2 days) for a period of 6 days after they were fixed, stained with 0.1% Crystal Violet 
solution and scanned. (Unt. = untreated). 
 
It is important, first of all, to alert the reader to the fact that in these CFs assays each 
untreated (no doxycycline) well is the control of the subsequent wells treated with ABT-263 
(Figure 16). It would be a mistake to proportionally compare the different condition arms 
because in each one the original seeding cell numbers were different. The rationale behind 
it has to do with the senescence state induced by the combination of Palbociclib and 
CDK2KD, making logical to seed cells at higher confluency at the beginning of the 
experiment. Cells treated with Palbociclib alone or untreated (still proliferating) were seeded 
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in fewer numbers so that the control wells would reach full confluency at the end of the 
experiment time. 
The cell lines in which ABT-263 treatment killed preferentially senescent cells were 
HCC1806 and SUM159PT. Although, in HCC1806 cells treated with Palbociclib alone, the 
two different shRNAs used (sh76 and sh77) show a different phenotype when treated with 
5 µM of ABT-263. With respect to CAL-120 and MDA-MB-157, this experiment did not 
reveal big differences between the effect of ABT-263 on cells treated with Palbociclib alone 
and cells treated in combination with CDK2KD.  
Also here these experiments should be repeated after an optimization of the ABT-
263 doses. Perhaps with doses lower than 5 µM we can find a better therapeutic window for 
ABT-263.  Most cell lines are already sensitive to 5 µM ABT-263 in the baseline (Figure 
16). We used this dose of ABT-263 based on previous experiments with CAL-51 cells. We 
assumed that 5 µM was a safe concentration to kill only senescent (and not proliferating) 
cells. A titration of ABT-263 should be performed to assess the sensitivity of the TNBC cell 
line panel to this senolytic agent. 
 
2.2.4. Killing pharmacological-induced senescence cells with ABT-263  
 
Obviously at the end of the day what really matters is to translate and recapitulate the 
genetic models to a pharmacological setting. Thus, using the same cell lines, we tested two 
small molecule inhibitors targeting CDK2: CVT-313 and Indisulam.156 The two drugs act 
by two different molecular mechanisms. CVT-313 directly inhibits CDK2 phosphorylation 
(which Western blots failed to show because of the poor quality of the p-CDK2 antibodies) 
inhibiting cell proliferation at the G1 to S phase transition.157 On its turn, Indisulam also 
arrests cells in G1 phase by suppressing the binding of the Cyclin E/CDK2 complex, 
resulting in the decrease of CDK2 levels.158  
In Figure 17A is shown the Western blots of the cells for senescence markers. The 
CDK2 levels are in general decreased, but cell lines respond differently to the two inhibitors. 
For instance, Indisulam is more effective in reducing CDK2 levels in CAL-51 and CAL-120 
whereas CVT-313 is more efficient in SUM159PT and MDA-MB-157. As for the case of 
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HCC1806, at a concentration of 2 µM, Indisulam proved to be lethal whereas with 5 µM 
CVT-313 there was no reduction of CDK2 levels at all. Once that 2 µM of Indisulam in 
combination with 1 µM of Palbociclib efficiently killed all cells without the application of 
the second punch with ABT-263 treatment, in the next experiments a lower dose of 
Indisulam could be tested.  
In fact, HCC1806 was the only cell line in which this small molecule inhibitor (CVT-
313) does not seem to have any effect in promoting senescence in combination with 
Palbociclib. These cells were still proliferating, and did not show any reduction of p-RB 
levels, did not stain for SA-β-galactosidase activity (Figure 17B) neither displayed a typical 
morphology of senescent cells. This absence of phenotype could be a drug dose-related issue 
and thus it would be worthy to repeat the experiment with a higher dose of CVT-313, but in 
general, using doses even higher than this can compromise the use of a drug in vivo. The 
toxicity conferred by this inhibitor has been related to off-target effects159,160 thus, the 
development of better CDK2 inhibitors is still needed. 
When treated with Palbociclib alone all cell lines, with the exception of CAL-51, did 
not stain for SA-β-galactosidase activity. In SUM159PT cells the observed staining was due 
to the background caused by the over confluency; in addition the morphology of those cells 
also did not display a senescence phenotype. On the other hand, when cells were treated with 
the combination of Palbociclib + CDK2 inhibitors the SA-β-galactosidase activity staining 
was positive and the typical senescence morphology was also visible. Nevertheless, it is also 
important to mention that for CAL-51 Palbociclib treatment alone also conferred similar 
morphology and SA-β-galactosidase activity, as already seen in the previous section. 
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Figure 17: ABT-263 treatment upon CDK2/4/6 pharmacological inhibition. 
A panel of 5 TNBC cell lines was treated with two CDK2 inhibitors (Indisulam (2 µM) and CVT-313 (5 µM)) 
and with Palbociclib for a period of 10 days. Cells were treated with different Palbociclib concentrations (note 
that these concentrations are different from the ones used in the genetic approach). (A.) cells were seeded for 
biochemistry analysis of senescence biomarkers (p21, p16, p-RB), CDK2 levels and two of its binding partners 
(cyclin E and cyclin A). HSP90 as a loading control. Simultaneously, cells were seeded at different low 
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densities in 6-well plate setting and continued to be treated with Palbociclib and the CDK2 inhibitors, and with 
ABT-263 (drugs refreshed every 2 days) for 8 days after which the wells without ABT-263 treatment (control 
wells) were fixed and stained for the senescence biomarker SA-β-galactosidase activity (B), and later stained 
with 0.1% Crystal Violet solution and scanned (C). (Unt. = untreated; PD = Palbociclib). 
 
Biochemically, the senescence markers revealed a similar phenotype with the one 
observed with the genetic approach described in the previous section. Excluding HCC1806, 
RB phosphorylation was downregulated both when treated with Palbociclib alone and in 
combination with the CDK2 inhibitors but to a greater extent in the combination. The same 
similarities were observed with the levels of Cyclins. In this pharmacological approach, the 
levels of Cyclin A protein expression were impaired but not the levels of Cyclin E. 
All together we can conclude that it is possible to induce senescence with CDK2/4/6 
inhibitors in TNBC. 
MDA-MB-157 cell line seemed to be the one in which our senescence model better 
validates, despite the lack of the detection for p21 and p16, p-RB is proportionally reduced 
with the levels of CDK2 inhibition when using the two different inhibitors. These results 
were in accordance with the CFs where we could see that when treated with CVT-313 the 
ABT-263 effect was stronger compared to when cells were treated with Indisulam (Figure 
17C). Important to recall that, as in the genetic approach, here each untreated well at different 
conditions works as a control to the other wells. The same proves to be true for SUM159PT, 
the CFs show a greater sensitivity to ABT-263 when cells are in a senescence state induced 
by the combination of CDK2/4/6 inhibitors. In both cases (SUM159PT and MDA-MB-157) 
there is a parallel between CDK2 reduction levels, after the drugs (CDK2 inhibitors and 
Palbociclib), and the senolytic effect of ABT-263. That is, a greater impairment in CDK2 
levels correlates with a stronger effect of ABT-263. 
In general, the induction of senescence state through our proposed model seems to 
work, although some optimization is still needed, namely proliferation assays to determine 
which Palbociclib and CDK2 inhibitors concentrations demonstrate better synergy in 
inducing senescence for each cell line, perform titrations matrices with CellTiter-Blue to 
quantify cell viability upon treatment with ABT-263, as well as to take more controls into 
account, for instance, look into the effect of the CDK2 inhibitors alone and in combination 
with ABT-263 treatment. 
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2.2.5. General discussion and conclusions 
 
TNBC therapy needs improvement. Researchers all over the world are working on 
finding new cancer vulnerabilities that can be exploited to improve the current therapies. 
 Through a genetic screen trying to find synthetic lethal interactions with the CDK4/6 
inhibitor Palbociclib in TNBC cell lines, we ended up uncovering a model of induction of 
senescence. In this model a CDK2 knockdown in combination with Palbociclib treatment 
induces senescence. 
The role of senescence cells has both been linked with tumor suppression as well as 
a promoter of tumorigenesis, but generally it is fair to say that cellular senescence is an anti-
cancer mechanism that is partially subverted by cancer. Interestingly, senescent tumor cells 
exist spontaneously within the heterogeneous population in a tumor and it is now known that 
tumor cells undergo senescence in response to chemo and radiotherapy.161 This is relevant 
because subpopulations of spontaneous senescent cells and therapy-induced senescence cells 
might lead to a compensatory resistance to apoptosis via alternative signaling pathways, and 
although in a senescent state, they remain still to be cancer cells with the ability to promote 
tumorigenesis. 
We validated the induction of senescence both with a genetic and a pharmacological 
approach. While the main focus of this thesis was TNBC, we also have shown that the model 
can be extended to other cancer types as well. This strategy could then be used in 
combination with a second treatment using a senolytic agent able to specifically eliminate 
senescent cells.  
It was challenging to compare the results of the two different approaches experiments 
since they contradict each other in some cases. Looking at CAL-51, for example, we did not 
expect such notorious difference in the CFs phenotype where, with the genetic approach it 
seems that ABT-263 does not have any effect, whereas with the small molecules CDK2 
inhibitors we can appreciate the opposite. Making it even more confusing is the fact that the 
biochemistry and SA-β-galactosidase staining are comparable in both approaches. 
The presence or absence of the senescence phenotype cannot be explained by the 
genetic background of TNBCs. One of those genetic traits that we thought it could give us 
some explanation to the different phenotype responses was the status of the p53 protein. 
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Given the role of p53 in senescence, it is very intuitive to think that the CDK2/4/6 inhibition 
senescence phenotype is p53 dependent. However, because of the several p53 mutant cell 
lines (Table 3, Materials and Methods) that also display senescence features, this doesn't 
seem to be a p53 dependent event. As the mechanistic explanation of the phenotype was not 
in the scope of this thesis, this matter is not going to be discussed further.  
Despite some confounding results concerning the effectiveness of ABT-263 in 
specifically kill senescence cells, we showed that indeed ABT-263 reveals a certain degree 
of selectivity towards senescent cells. In addition, the fact that studies have been reporting 
the existence of therapy-induced senescence cells in patient tumors only reinforces further 
the need for the development of novel senolytic drugs that can eventually be used to target 
senescent cancer cells that have acquired resistance to chemo and radiotherapy.  
The CDK2 inhibitor Indisulam was already been used in the clinic and have shown 
tolerable toxicity,158,162 which can be an advantage over others CDK2 inhibitors. However, 
there was no clear distinction between which of the two CDK2 inhibitors used in this study 
—Indisulam or CVT-313— is the most efficient in promoting senescence in combination 
with Palbociclib. Given the lack of more efficient CDK2 inhibitors and their different and 
complementary mechanisms of action, future experiments could be done to assess if the use 
of these two CDK2 inhibitors together would prove to be more efficient in inhibiting CDK2. 
If so, a triple combination with Palbociclib could at the end be even more beneficial. 
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2.3. Summary and future directions  
 
In the first part of the project, we showed that all the four candidate genes extracted 
from a functional genetic screen aiming to find synthetic lethal interactions with hypoxia 
proved to not validate. With this work we were hoping to find lethal interactions with 
hypoxia that could be then pharmacologically targetable. The goal was to improve the 
already used AA therapies that so far have not shown clinical relevance.  
The failure, up until now, in identifying synthetic lethal interaction with hypoxia 
despite the many attempts, suggests that hypoxia regulation and adaptation are processes 
that we still do not fully understand. Regardless, more work should be done to find the 
weaknesses that hypoxia impose over cancer cells. Perform more in vitro functional genetic 
screens with different libraries and with different cancer types would be interesting 
experiments to do, as well as in vivo screens could reveal new insights in finding essential 
genes with antiangiogenic therapy.  
The second part of this project showed more promising results. We were able to 
validate the finding that CDK2 knockdown/knockout in combination with Palbociclib 
treatment induces senescence in TNBC and that these senescence induced cells can be 
targeted with senolytic agents to be specifically eliminated. Although we only tested ABT-
263 as senolytic there are more drugs that can be tested in the scope of this one-two punch 
strategy. As it was not under the objectives of this thesis, the mechanistic explanation behind 
this induced senescent phenotype was not assessed with more detail. Nevertheless, this 
phenotype does not appear to be p53 dependent. 
 The next step would be to implement this strategy in an in vivo setting. Ideally, first, 
we would engraft CDK2 deficient tumors (and appropriate controls) in mice, treat with 
Palbociclib and evaluate the subsequent effects of ABT-263. If this first experiment shows 
positive results, then a similar protocol would be performed using CDK2 pharmacological 
inhibitors (CVT-313 and Indisulam) instead of the genetic approach. 
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3. Materials and Methods 
 
3.1. Cell culture 
 
A total of 13 cell lines were used during this project. HEK-293T cell line was used 
for lentivirus production. In the validation of the hypoxia screen only SUM159PT was used; 
and for the senescence model validation, to better represent the heterogeneity in TNBC, a 
panel of nine TNBC cell lines was used: SUM159PT, SUM149PT, CAL-51, CAL-120, 
MDA-MB-157, SK-BR-7, HCC1806, HCC70 and HCC1937. As well as SW1463, a 
colorectal cancer cell line, and H2122 and H1944, two lung cancer cell lines. Cells were 
cultured at 37 ºC at 5% CO2. At normoxia conditions the oxygen percentage was 21% and 
in hypoxia around 1%.  
 
Table 2: List of the cell lines used, culture medium composition and cell seeding numbers for colony 
formations assay. 
Cell line Composition of the culture medium  CF 6-well setting seeding 
number 
CAL-51 DMEM 20% FBS; 1% Pen./Strep. 10.000 
CAL-120 DMEM 10% FBS; 1% Pen./Strep. 30.000 
SUM159PT DMEM-F12 5% FBS;  
1% Pen./Strep; 
5µg/ml Insulin;  
1µg/ml 53,5 µl Hydrocortisone 
10.000 
SUM149PT DMEM-F12 5% FBS; 
 1% Pen./Strep; 
5µg/ml Insulin;  
1µg/ml Hydrocortisone 
20.000 
SK-BR-7 DMEM-F12 10% FBS;  
1% Pen./Strep. 
30.000 
MDA-MB-157 RPMI 1640 10% FBS; 
 1% Pen./Strep. 
20.000 
HCC1806 RPMI 1640 10% FBS;  
1% Pen./Strep. 
10.000 
HCC70 RPMI 1640 10% FBS;  
1% Pen./Strep. 
50.000 
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HCC1937 RPMI 1640 10% FBS;  
1% Pen./Strep. 
50.000 
SW1463 RPMI 1640 10% FBS;  
1% Pen./Strep. 
30.000 
HEK293T DMEM 10% FBS; 
1% Pen./Strep. 
 
H2122 DMEM 10% FBS; 
1% Pen./Strep. 
30.000 
H1944 DMEM 10% FBS; 
1% Pen./Strep. 
30.000 
 
Fetal Bovine Serum (FBS) (Thermo Scientific); Penicillin/Streptomycin antibiotics 
(Gibco); Insulin (Sigma Aldrich); Hydrocortisone (ref); DMEM, DMEM-F12 and RPMI 
1640 culture mediums (Gibco). 
 
Table 3: List of cell line mutations. 
Cell line p53 p21 p16 kRas 
CAL-51 WT WT WT WT 
CAL-120 Mut. (homozygous) WT WT WT 
SUM159PT Mut. WT Mut. (homozygous) WT 
SUM149PT Mut. WT null WT 
SK-BR-7 WT WT WT Mut. (heterozygous) 
MDA-MB-157 Mut. (heterozygous) WT WT WT 
HCC1806 Mut. (heterozygous) WT WT WT 
HCC1187 Mut. (heterozygous) WT WT WT 
HCC1395 Mut. (homozygous) WT WT WT 
HCC1937 Mut. (homozygous) WT WT WT 
HCC70 Mut. (homozygous) WT WT WT 
SW1463 (CRC) Mut. (homozygous) WT WT Mut. (homozygous) 
H1944 (Lung) WT WT WT Mut. (heterozygous) 
H2122 (Lung) Mut. (heterozygous) WT WT Mut. (homozygous) 
 
 
 
 
53 
 
3.2. Colony formation assays 
 
Culture medium and drugs were refreshed every 2-3 days. When the control wells, 
containing cells not subjected to treatment, were confluent the experiment ended and cells 
were fixed with a 2% formaldehyde in phosphate buffered saline (PBS) for 1 hour followed 
by a staining step using a 0.1% crystal violet solution (dissolved in water) for about 20 
minutes; then this staining solution was removed and the excess was gently rinsed with 
water, finally the plates were left to dry overnight and scanned the next day. Table 4 shows 
the list of drugs used during this project. 
Table 4: List of drugs used during the project and their targets. 
Drug Target Stock concentration in 
DMSO (mM) 
THZ1 CDK7 5 
Palbociclib CDK4/6 5 
Indisulam Cyclin E/CDK2 complex 10 
CVT-313 CDK2 10 
ABT-263 Bcl-XL, Bcl-2, Bcl-w 10 
 
3.3. Cell growth assay 
 
SUM159PT cells were seeded in 6-well setting (10.000 cells per well) under hypoxia 
and normoxia conditions. Cells were washed with PBS, collected and counted at different 
time points (triplicates counted twice) and, at the same time, fixed and stained. 
 
3.4. Western Blot 
 
Cells were seeded in 6-well plate wells prior to the day of harvest with high-density 
numbers (200.000 – 300.000 cells). First the medium was removed and cells washed with 
cold PBS (plates placed on ice), RIPA buffer (25 mM Tris – HCl pH 7.6, 150 mM NaCl, 1% 
sodium deoxycholate, 0.1% SDS) containing phosphatases inhibitors (phosphatase 
inhibitors cocktail II and III (Sigma)) and complete protease inhibitor (Roche) was then 
added to the wells which were then scratched with a cell lifter; samples were incubated on 
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ice for 30 minutes, vortexed every 10 minutes, and then centrifuged at 14000 rpm at 4º C for 
10 minutes. The concentration of protein was quantified by Bicinchoninic Acid (BCA) assay 
(Pierce BCA, Thermo Scientific) and samples were normalized to the same quantity of 
protein and added with DTT redox agent  for the denaturation step that followed by 5 minutes 
of heating at 95º C; after denatured, samples were loaded into precast 4-12% polyacrylamide 
gel (Invitrogen) where they were separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDA-PAGE) for around 1 hour at 200 volts after which they were then 
transferred to a polyvinylidene fluoride (PVDF) membrane (at 330 or 660 mA for 60-90 
minutes). Next, the membranes were blocked in a 5% milk blocking solution in PBS-0.1% 
Tween-20 (PBS-T) for 60 minutes followed by the incubation with the primary antibody 
diluted 1:1000 in blocking buffer, with constant shaking, at 4º C overnight. Membranes were 
washed 3 times (10 minutes each) in PBS-T, followed by the incubation with the appropriate 
secondary antibody diluted 1:10,000 in blocking buffer at room temperature and constant 
shaking for 1 hour; again, membranes were washed with PBS-T 3 times for 10 minutes. 
Finally, a chemiluminescence substrate (Pierce ECL, Thermo Scientific) was added to the 
membranes (placed between plastic sheets) and were placed in a ChemiDoc machine (Bio-
Rad) that detected the chemiluminescence signals emitted. Table 5 shows the list of 
antibodies used in this project. 
 
Table 5: List of antibodies used for Western blot during this project. 
Target protein Isotype Predicted Molecular 
weight (kDa) 
Brand  
Hypoxia-inducible factor 1-
alpha inhibitor (FIH-1) 
Rabbit 40 Novus 
Runt-related transcription 
factor 1 (RUNX1) 
Mouse 49 Abcam 
Putative Polycomb group 
protein ASXL2 
Rabbit 238 Bethyl 
Histone-binding protein 
RBBP7 
Rabbit 52 Bethyl 
Cyclin-dependent kinase 2 
(CDK2) 
Mouse 34 Santa Cruz 
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Retinoblastoma-associated 
protein (RB) 
(phosphorylated) 
Rabbit 110 Cell signaling 
Cyclin-dependent kinase 
inhibitor 1 (p21) 
Mouse 21 Santa Cruz 
Cyclin-dependent kinase 
inhibitor 2A (p16) 
Mouse 16 Santa Cruz 
Bcl-2-like protein1 (Bcl-Xl) Rabbit 30 Cell signaling 
Cyclin E Rabbit 53 Santa Cruz 
Cyclin A Rabbit 54 Santa Cruz 
Heat shock protein HSP 90-
alpha (HSP90) 
Mouse 90 Santa Cruz 
 
 
3.5. qRT-PCR  
 
To assess RUNX1 knockdown levels, SUM159 cells were collected after 
transduction with lentiviral particles carrying shRNA sequences targeting RUNX1 
(sequences on table Y) and two days of puromycin selection. RNA was isolated using Isolate 
II Genomic RNA kit (Bioline) according to manufacturer instructions. The yield of RNA 
extraction was measured using the Nanodrop ND1000 system. cDNA was obtained by 
reversed transcription using Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) 
for qRT-PCR according to manufacturer’s protocol, using 1 µg of RNA per sample. Gene 
expression was detected by SYBR Green assay using the AB 7500 Fast Real-time PCR 
system, following the manufacturer’s instructions. 
 
3.6. Cloning of the sgRNA’s for the hypoxia screen validation 
 
Table 6 shows all the sgRNA’s oligonucleotide sequences that were cloned to target 
and edit each gene (sequences were chosen from the CRISPR epigenetic library and 
purchased from Invitrogen). 
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Table 6: List of the sgRNA sequences used to target the top four gene hits of the hypoxia screen. 
RUNX1 gene had six sgRNA that come up as a hit followed by HIF1AN, ASXL2 and RBBP7 each one with 
three single guides. 
 
 
Five micrograms of vector pLentiCRISPR2.1 were linearized by digesting with 2 µL 
of BsmBI enzyme, in 5 µl of Buffer 3.1, and mQ water up to 50 µl; this digestion was 
incubated for 4 hours at 55 °C. The product of the digestion was run on a 1x TAE (0.6% 
agarose) gel with SYBR-safe DNA staining, and the DNA (digested) was recovered using a 
DNA purification kit (Isolate II Genomic DNA kit (Bioline). The oligonucleotide sequences 
were cloned into the vector in a reaction mixture with 50 ng of the digested DNA backbone, 
1 µl from 100 µM from oligonucleotide solution, mQ water up to 10 µl and 10 µl of GIBSON 
assembly mix (New England BioLabs), and was allowed to incubate for 1 hour at 50 °C. The 
next step was to electroporate this vector into Endura competent bacteria (Lucigen). In an 
Eppendorf tube (work on ice) 43 µl of mQ water, 2 µl of the GIBSON assembled product 
and 5 µl of bacteria were mixed, transferred into a pre-chilled electroporation cuvette and 
electroporated around 1.8 kV. Immediately after 500 µl of LB (Lysogenic Broth) medium 
(20 g of LB Broth Lennox in 1L of deionized water followed by an autoclave step) was 
added and the electroporated bacteria suspension was transferred to an Eppendorf tube and 
incubated for 1 hour at 37 °C while shaking. Twenty-five microliters of this bacteria 
suspension were then plated on LB agar supplemented with carbenicillin plates (20 g of LB 
Broth Lennox, 15 g of Bacto-Agar in 1L of deionized, autoclaved and 1 mL of carbenicillin 
was added) and let to grow overnight at 37 ºC. Next day, 2-3 colonies from each construct 
were randomly picked and let to grow up in 5 mL LB + carbenicillin (1000x from 100 
mg/mL stock) medium and let grow overnight. Next morning, DNA plasmids were isolated 
using Invitrogen PureLink Genomic DNA mini Kit, according to manufacturer’s protocol, 
screen rank Ordered oligo ID gRNA sequence
1 CTTGTGGAAAGGACGAAACACCGGGTAGGTGGCGACTTGCGGTgt t t aagagct agaaat agcaag RUNX1-11 GGTAGGTGGCGACTTGCGGT
2 CTTGTGGAAAGGACGAAACACCGGCCATCTGGAACATCCCCTAgt t t aagagct agaaat agcaag RUNX1-6 GCCATCTGGAACATCCCCTA
3 CTTGTGGAAAGGACGAAACACCGCACTTACTTCGAGGTTCTCGgt t t aagagct agaaat agcaag RUNX1-2 CACTTACTTCGAGGTTCTCG
4 CTTGTGGAAAGGACGAAACACCGCACTTCGACCGACAAACCTGgt t t aagagct agaaat agcaag RUNX1-3 CACTTCGACCGACAAACCTG
5 CTTGTGGAAAGGACGAAACACCGGCACTTACTTCGAGGTTCTCgt t t aagagct agaaat agcaag RUNX1-5 GCACTTACTTCGAGGTTCTC
6 CTTGTGGAAAGGACGAAACACCGTACCGCAGCCATGAAGAACCgt t t aagagct agaaat agcaag RUNX1-14 TACCGCAGCCATGAAGAACC
7 CTTGTGGAAAGGACGAAACACCGGACGCGGAATGGGCCTAGTCgt t t aagagct agaaat agcaag HIF1AN-6 GACGCGGAATGGGCCTAGTC
8 CTTGTGGAAAGGACGAAACACCGTTCATCCCAGGCGGGGCCGAgt t t aagagct agaaat agcaag HIF1AN-10 TTCATCCCAGGCGGGGCCGA
9 CTTGTGGAAAGGACGAAACACCGGCAGTTATAGCTTCCCGACTgt t t aagagct agaaat agcaag HIF1AN-7 GCAGTTATAGCTTCCCGACT
10 CTTGTGGAAAGGACGAAACACCGCGCACCTGTCGATCTACCTCgt t t aagagct agaaat agcaag ASXL2-4 CGCACCTGTCGATCTACCTC
11 CTTGTGGAAAGGACGAAACACCGGCACCTGTCGATCTACCTCTgt t t aagagct agaaat agcaag ASXL2-7 GCACCTGTCGATCTACCTCT
12 CTTGTGGAAAGGACGAAACACCGCTGCGATGGATGAAACGGCAgt t t aagagct agaaat agcaag ASXL2-6 CTGCGATGGATGAAACGGCA
13 CTTGTGGAAAGGACGAAACACCGACCCTTGTCACTGTCACAATgt t t aagagct agaaat agcaag RBBP7-2 ACCCTTGTCACTGTCACAAT
14 CTTGTGGAAAGGACGAAACACCGTCTGCGGCATGTAACGAGCAgt t t aagagct agaaat agcaag RBBP7-16 TCTGCGGCATGTAACGAGCA
15 CTTGTGGAAAGGACGAAACACCGTGACCTCTTAATCTGAGATCgt t t aagagct agaaat agcaag RBBP7-17 TGACCTCTTAATCTGAGATC
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and its concentration measured using a Nanodrop ND10000 system. To confirm if the oligos 
were successfully cloned, a solution mixture of 500 ng of plasmid DNA in mQ water up to 
15 µl, 1 µl of hU6-343 primer (10 µM) and 4 µl of BigDye Terminator v3.1 Cycle 
Sequencing Kit (Thermo Fisher) was prepared and submitted to PCR (5 minutes at 96 ºC 
followed by 30 cycles of 30 seconds at 96 ºC, 15 seconds at 50 ºC and 4 minutes at 60 ºC, 
ending with “infinite” time at 10 ºC); the PCR samples were sent to sequence and the 
insertions were confirmed using the SnapGene program. 
 
3.7. Lentivirus production 
 
E.coli bacteria (from the whole genome TRC library - stored at -80 °C in glycerol 
stocks), which contain a pLKO vector with an insert of shRNA targeting RUNX1 and an 
antibiotic resistance marker were picked. Bacteria were cultured overnight at 37 °C in 2X 
LB medium (20g of Bacto-Tryptone, 10g of yeast extract, 10g of NaCl in 1L of water) with 
carbenicillin. Plasmid DNA was isolated from the bacteria using a standard DNA isolation 
protocol (from Roche), after which the DNA concentration was measured (using a Nanodrop 
ND1000 system). Lentivirus particles were prepared by transfecting HEK293T cells with 
plasmid DNA from the shRNA library. To do that, we mixed 1 µg of plasmid DNA of our 
library, 1 µg of lentivirus packaging mix (pMD2.G envelope plasmid and pMDLg/pRRE 
packaging plasmid) and 6 µL of polyethylenimine (PEI) in 100 µL DMEM medium 
(quantities used in a 6-well plate setting). The mix was vortexed briefly, incubated for 15 
minutes at room temperature and added to one million HEK293T cells seeded the day before 
in 2 mL of DMEM medium. Cells were incubated overnight; the next day the medium was 
refreshed; after 48 hours of incubation, the medium containing the lentivirus was filtered (by 
20-μm filters), collected and stored at -80°C. 
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3.8. Using shRNA-CDK2 doxycycline-inducible system for the cellular 
senescence induction validation 
 
Eight TNBC cell lines (CAL-51, CAL-120, SUM159PT, MDA-MB-157, 
HCC19937, HCC1806, HCC70 and SK-BR-7) were transduced with three different 
doxycycline-inducible shRNAs targeting CDK2 (sh40/76/77, from Dharmacon).  Twenty-
four hours after the transduction cells were selected with puromycin (1 μL/mL) for 48h. 
When the selection was finished, cells were trypsinized and reseeded for experiments. 
Doxycycline was added daily to the medium to keep a constant expression of the shRNA 
inducible system. Doxycycline activates both the shRNA system and the expression of an 
RFP reporter, which can be used to visually confirm the level of shRNA-CDK2 induction (a 
control without doxycycline addition was used for each cell line). 
 
3.9. Fluorescence-activated cell sorting  
 
Cells were sorted into single cells at the Flow Cytometry Facility of the Institute. A 
cell suspension of 10 million cells/ml were handed out to the FACS facility that performed 
the sorting.  
Isolate single cells using FACS sorting presents some hurdles. Many of the isolated 
single cells end up not surviving since it is hard for cells to divide when they do not have the 
presence of neighboring cells. Another issue is that this technique oftentimes cannot isolate 
exactly just one cell, putting in the same well two or more cells, which is then visible at the 
microscope as the growth multiple colonies in different parts of the well, so when that 
happened those cells were discarded 
 
3.10. β-Galactosidase staining 
 
Cells were washed twice with PBS and then stained for β-Galactosidase using a 
Senescence β-Galactosidase Staining Kit (Sigma) according to manufacturer’s protocol. 
Cells were left to stain overnight until a maximum period of 48h (the time required for the 
staining to be visible varies among cell lines). 
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